GMG Unveils Graphene Aluminium-Ion Battery That Fully Charges in 6 Minutes ACN Newswire

GMG Unveils Graphene Aluminium-Ion Battery That Fully Charges in 6 Minutes

Brisbane, Australia--(ACN Newswire via SeaPRwire.com - December 15, 2025) - Graphene Manufacturing Group Ltd. (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to provide the latest progress update on the Graphene Aluminium-Ion Battery technology ("G+AI") being developed by GMG and the University of Queensland ("UQ") under a Joint Development Agreement with Rio Tinto, one of the world's largest metals and mining groups, and with the support of the Battery Innovation Center of Indiana ("BIC") in the United States of America.Based on its current state of development as reflected below, the GMG G+AI Battery has similar performance characteristics to those provided by High Power Lithium Titanate Oxide ("LTO") batteries, which are sold at a premium price of up to US$1500/kWh. However, the GMG G+AI Battery can be produced at a substantially lower cost and therefore can be priced below that of LTO batteries. In 2025, sales of LTO batteries, which are used in many applications globally, totalled US$ 5.6[1] billion.Battery Performance Update:GMG is pleased to announce that it has progressed its G+AI Battery technology and believes that, once development is completed, it can meet the key target specification requirements for the main targeted battery use case as per Figure 1, including:Charging in under 6 minutes;Energy density > 100 Wh/kg after 1 hour of charging;Long Cycle Life (10,000 cycles);Safe (no Lithium);Lower Thermal Runaway Risk; andLikely no thermal management system will be needed.Bob Galyen, GMG Non-Executive Director, commented: "In my nearly five decades in the battery industry, I have rarely seen a technology with the disruptive potential of GMG's next-generation graphene aluminium-ion battery. With the possibility of charging from empty to full in around six minutes, this chemistry fundamentally changes how designers can think about electric vehicles, consumer electronics, and stationary storage. Instead of planning around long charge stops with large packs, engineers can optimise for rapid energy turnaround, with higher power, and safer, with GMG's battery made from abundant raw materials. Lithium-ion will remain a key part of the energy landscape for years to come, but its limitations in fast charging, temperature tolerance, and critical-mineral supply are increasingly evident. By leveraging aluminium and graphene, the GMG team is demonstrating a pathway to reduce reliance on traditional lithium-based systems while delivering step-change improvements in charge time and power density. This is not an incremental tweak to existing cells - it is a new platform that can open markets and use cases that were previously uneconomic or impractical. As GMG moves from the lab toward scaled manufacturing, its primary focus is on proving reliability, safety, and cost at industrial level. Automotive, grid, and specialty-device partners are already engaging with GMG to explore pilot programs and early integrations. The companies that adapt quickest to this shift will lead the next wave of electrification, and GMG intends to be at the centre of that transition with graphene aluminium-ion technology."Figure 1: G+AI Battery Use Case - heavy mobile equipmentTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/278044_gmg_figure1.jpgGMG is pleased to share the energy densities of the current GMG G+AI pouch cell at 60 minutes and 6-minute charging compared to other chemistry batteries on the market (Figure 2), and a voltage vs capacity graph (Figure 3) of its latest G+AI Battery technology based on data provided by the third-party BIC battery testing laboratory.Based on that testing, the current stage of development, batteries produced by GMG and BIC had an energy density of 58 Wh/kg when charged in 1 hour and 26 Wh/kg when charged in 6 minutes. In 6-minute fast charging, the battery cells achieved 62% capacity in 3.2 minutes. The batteries had a nominal voltage of approximately 3.0 Volts and maintained performance over hundreds of cycles at 6-minute fast charging, without the significant degradation typically observed in lithium and sodium-ion batteries at such high charging rates.Figure 2: Different Battery Chemistry Performance at 6 min and 60 min Charge[2]To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/278044_3e8dbe4f44c75b4b_002full.jpgStandard commercial Lithium Nickel Manganese Cobalt ("LNMC") and Lithium Iron Phosphate ("LFP") battery cells for electric vehicles and stationary storage are not designed for continuous 6-minute charging (10C); typical recommended charge rates are ≤1 hour (1C), often 2 hours (0.5C), with only limited fast charge operation. Only specialized high-power cell designs like LTO battery cells can tolerate charge rates of 6 minutes (10C).[3]Figure 3: Battery performance curves of GMG's G+AI Battery at 60 min and 6min chargeTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/278044_3e8dbe4f44c75b4b_003full.jpgGMG has now developed a completely new hybrid electrolyte that is chloride free and noncorrosive, unlike common aluminium battery electrolytes, along with a complex cathode and anode technology that enables very stable fast charging over several cycles. The substrate for both the cathode and anode in the GMG G+AI Battery is aluminium foil - which provides significant cost and weight savings compared with copper, the substrate material used in most lithium and sodium-ion batteries. GMG's technology does not include the use of lithium or copper. The Company has submitted an additional patent application covering these new developments.Craig Nicol, GMG Managing Director and CEO, commented: "I couldn't be happier with the GMG team to get to this point with our battery. We have rebuilt this battery in our weekly sprints from the ground up and developed completely new complex cathode, anode and electrolyte. This will provide a next generation fast charging battery technology currently not available in the world, and we look forward to sending out sample cells to test with partners in early 2026. This technology has many years of development in front of it and will improve as we keep pushing through known issues to improve capacity, voltage and reduce weight."GMG management believes that the Company's battery technology can eventually achieve over 150 Wh/kg when charged in 1 hour, and over 75 Wh/kg when charged in 6 minutes. The Company believes further development of the cathode, anode, electrolyte and component weights will eventually achieve this end goal.Figure 4 shows the latest Graphene Aluminium-Ion Battery multi-layer pouch cell.Figure 4: Current Multi-Layer Battery Pouch CellTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/278044_3e8dbe4f44c75b4b_004full.jpgBattery Technology Readiness LevelThe battery technology readiness level ("BTRL") of the G+AI technology remains at Level 4, see Figure 5. GMG is currently optimizing electrochemical behaviour for pouch cells via ongoing laboratory experimentation. Through collaboration with BIC, it is anticipated that the battery technology readiness will progress to BTRL 7 and 8 since the equipment and processes needed to produce the G+AI batteries are the same as those employed to make Lithium-Ion Batteries.Figure 5: Battery Technology Readiness Level (BTRL)To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/278044_3e8dbe4f44c75b4b_005full.jpgThe Company is confident it can meet the overall timeline, as seen in Figure 6, of its battery cell roadmap that calls for testing of cells with customers in 2026 and small commercial production with support of various partners, including BIC, in 2027.Figure 6: Battery Cell RoadmapTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/278044_3e8dbe4f44c75b4b_006full.jpgNext Steps Toward Commercialisation & Market ApplicationsJack Perkowski, GMG Chairman and Non-Executive Director, commented: "I am extremely proud that GMG has progressed its battery to this stage. It is a significant milestone for the Company because the battery technology has so much opportunity in so many applications - especially in commercial vehicles. I look forward to the next updates as GMG makes further progress in the development of its battery technology."The Company continues to see a broad range of applications for a completed GMG G+AI Battery - utilising its ultra-high power-density and economic energy density characteristics. Along with Rio Tinto, a range of global companies have confidentially expressed their interest in working with GMG in the following vertical sectors:Figure 7: Market ApplicationsTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/278044_3e8dbe4f44c75b4b_007full.jpgCurrently, GMG believes it will use a plastic battery pack design, similar to Figure 8, to hold the battery pouch cells - reducing the weight, cost and complexity of using a metal case. Using a plastic battery pack is possible for two main reasons - GMG believes that its battery will not require a thermal management system or the fireproofing precautions provided by the metal case in a lithium-ion battery. Using plastic will increase the comparative energy density of GMG's G+AI battery packs when compared to lithium-ion batteries.Figure 8: Expected Battery Pack for G+AIB Pouch CellsTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/278044_3e8dbe4f44c75b4b_008full.jpgComparison and Market Review: LTO Batteries As shown in Figure 9 below, the performance of GMG's G+AI battery technology is already very similar to LTO batteries.Figure 9: Comparison of Graphene Aluminium-Ion Battery (G+AI) to Lithium Titanate Oxide (LTO) BatteryParameterHigh Power LTO[4]GMG G+AI BatteryRapid Charging80% in 6 minutes100% in 6 minutesEnergy Density - 6-minute charge37 Wh/kg (80% of Capacity)46 Wh/kg (6 min +)26 Wh/kg(Current)Large upside to be confirmedDepth of DischargeFull RangeFull RangeSafetySafeSafer (no lithium fire potential)Longevity70% performance over 20,000 cyclesTo be confirmedBattery PriceUS$800 - US$1500 / kWh[5]Lower price due to lower material costsNo lithium, no TitaniumMarket SizeUS$5.6 Billion in Sales in 2025Under development LTO batteries are sold at a premium to LFP and LNMC batteries, which are the main chemistries used in electric vehicles and energy storage systems, and are also widely used in other electronic applications due to their high performance and long cycle life. The material and manufacturing costs for GMG's G+AI Battery are expected to be similar to, or less than, the cost to manufacture standard lithium-ion batteries, but substantially lower than the costs to produce LTO batteries.LTO batteries have energy density ranging from 50 - 80 Wh/kg.[6] The LTO product is sold globally for use in many applications - with a total of US$5.6[7] billion sales per annum in 2025. Sales of LTO batteries are expected to grow at 10% per annum to an estimated US$ 9.0 billion by 2030. The major manufacturers of LTO batteries include Toshiba, Gree, Microvast and CATL.Further details on applications for the LTO battery from Mordor Intelligence7 are described below. In many of the use cases for LTO batteries, GMG believes that its G+AI Battery can be substituted at a substantially lower cost.Commercial Vehicles: Automotive, primarily buses, refuse trucks, and drayage tractors rather than passenger cars, is the largest user of LTO batteries. Fleets realize five-year total-cost-of-ownership parity once fuel savings and lower maintenance offset higher upfront prices.Fast-charging Electric Buses and Trucks: Transit authorities need battery systems that accept repeated high-power "opportunity charges" during short layovers. LTO cells replenish 80% capacity in roughly five minutes, allowing operators to shrink fleet size without sacrificing route frequency. U.S. Low-No Emission Bus grants earmark more than US$1.5 billion per year, with bid specifications that explicitly reference rapid-charge capability. Parallel subsidy programs in China reimburse up to CNY 80,000 (US$ 11,396) per new-energy bus, accelerating volume deployment in provincial capitals.Hybrid and BEV: Regenerative braking and high-C-rate acceleration favour the use of LTO batteries. Use in fast-charge EV stations is growing rapidly as ride-hailing fleets adopt swap-ready models.Stationary Storage: Utility-scale batteries now cycle multiple times per day for frequency regulation, peak shaving, and voltage support. Energy-storage-system integrators adopt LTO batteries for grid-frequency response where state-of-charge swings are shallow but frequent.Industrial Robotics: LTO batteries are used in continuous-duty forklifts that require partial charges during operator breaks.Aerospace and Defense: Unmanned aerial vehicles, missile auxiliaries, and soldier-worn power banks operating from -40 °C to +60 °C ambient.5-minute Battery-Swap Stations: Battery-as-a-service platforms require ultra-fast turnaround and high cycle life. CATL confirmed plans to install 1,000 swap stations in 2025 and 30,000-40,000 by 2030, each requiring packs that tolerate thousands of rapid exchanges without degradation.Sub-10 kWh Packs: Cordless construction tools, autonomous ground vehicles, and medical carts select LTO batteries to bypass daily pack swaps.12V starter replacement to Lead acid: GMG's G+AI battery technology would be a viable 12 V starter-battery replacement for lead-acid, offering lower weight, longer cycle life, good low-temperature performance and improved cold-cranking capability, together with excellent tolerance to storage at 0% state of charge. In suitable system designs, the chemistry's stable voltage behaviour can also reduce balancing requirements and simplify battery management, helping to lower overall system cost.Lifecycle Procurement Preference: Many government procurement frameworks now weigh lifecycle reliability higher than purchase price. For example, New Mexico awarded a US$ 400 million bus electrification contract that included stringent thermal-runaway resistance metrics. Europe's Clean Industrial Deal allocates capital for storage technologies that stabilize renewables, aligning well with LTO batteries' fast-response profile.Cylindrical Cells: accounted for 37.7% of LTO battery sales in 2024 as entrenched production lines and robust steel casings satisfied heavy-duty demand. Pouch designs address aerospace weight requirements and constrained dashboards in autonomous robots.Summary of Important Milestones for GMG's G+AI Battery Development: MonthImportant Milestones in the Development of the Graphene Aluminium Ion BatteryMay 2020GMG and UQ win Australian Research Council grant for Graphene battery developmenthttps://graphenemg.com/gmg-and-uq-wins-australian-research-council-grant-for-graphene-aluminium-ion-battery-development/ Apr 2021The University of Queensland and GMG kick off coin cell battery development projecthttps://graphenemg.com/gmg-the-university-of-queensland-research-uni-quest-kick-off-the-graphene-enhanced-aluminium-ion-battery-development-project/May 2021Graphene aluminium-ion battery performance data - Energy Density and Power Densityhttps://graphenemg.com/gmg-graphene-aluminium-ion-battery-performance-data/Jun 2021Graphene aluminium-ion battery performance data - Cycle Lifehttps://graphenemg.com/graphene-aluminium-ion-battery-performance-data/Jun 2021Significant potential battery customer market response to launch of batteryhttps://graphenemg.com/gmg-graphene-aluminium-ion-battery-progress-update/Jul 2021Investment decision for coin cell battery development centrehttps://graphenemg.com/gmg-battery-pilot-plant-investment/Oct 2021Construction starts for coin cell battery development centrehttps://graphenemg.com/construction-battery-pilotplant/Oct 2021Bosch Australia Manufacturing Solutions and GMG sign Letter of Intenthttps://graphenemg.com/gmg-and-bosch-sign-collaboration-arrangement-for-bosch-to-design-and-deliver-gmgs-graphene-aluminium-ion-battery-manufacturing-plant/Dec 2021Commencement coin cell battery development centrehttps://graphenemg.com/battery-pilot-plant/Dec 2021Initial coin cell batteries sent for customer feedbackhttps://graphenemg.com/graphene-aluminium-battery-customers-prototypes/Mar 2022Initial factory acceptance testing of semi-automated prototype battery cell assembly equipmenthttps://graphenemg.com/gmg-announces-initial-factory-acceptance-testing-of-semi-automated-prototype-battery-cell-assembly-equipment/Mar 2022Wood Engineering and GMG Sign a Letter of Intenthttps://graphenemg.com/gmg-and-wood-agree-collaboration-arrangement-for-wood-to-engineer-and-deliver-major-graphene-manufacturing-expansion-projects/May 2022Rio Tinto and GMG sign Letter of Intenthttps://graphenemg.com/gmg-riotinto-energysavings-battery/Jun 2022Commissioning of Pouch Cell Equipmenthttps://graphenemg.com/gmg-manufactures-first-pouch-cell/Jun 2022Bob Galyen, former chief technology officer of CATL, joins GMG technical advisory committee.https://graphenemg.com/gmg-technical-advisory-committee-leadership-team-additions-and-cfo-change/Aug 2022Investment decision for Phase 1 modular Graphene Production Planthttps://graphenemg.com/gmg-announces-phase-1-expansion-project-to-graphene-manufacturing-facility-for-energy-saving-products-and-batteries/Oct 2022Significant battery performance, cell and graphene production improvementshttps://graphenemg.com/gmgs-battery-update-significant-battery-performance-cell-and-graphene-production-improvements/Dec 2022Investment of $600k Battery Development Centrehttps://graphenemg.com/gmg-invests-au-600000-to-accelerate-battery-pouch-cell-customer-testing-development-in-2023/Feb 2023Australian Government Approval (AICIS) for production and sale of batteries.https://graphenemg.com/gmg-receives-regulatory-approval-to-enable-significant-commercial-sales/May 2023Battery Joint Development Agreement with Rio Tinto signedhttps://graphenemg.com/gmg-announces-battery-joint-development-agreement-with-rio-tinto/May 2023Battery Technology Readiness Level (BRTL) 2-3 reachedhttps://graphenemg.com/gmg-announces-battery-team-and-related-updates/May 2023Decision to switch to develop Pouch Cells (instead of Coin Cells)https://graphenemg.com/gmg-announces-battery-team-and-related-updates/Jul 2023Bob Galyen former chief technology officer of CATL joins GMG board of Directorshttps://graphenemg.com/graphene-manufacturing-group-appoints-former-chief-technology-officer-of-catl-limited-to-its-board-of-directors/Sep 2023Battery Pouch Cell Prototypes Multilayered Auto-Stacker Demonstrationhttps://graphenemg.com/gmg-graphene-aluminium-ion-battery-pouch-cell-prototypes-multilayered-auto-stacker-demonstration/Sep 2023Reaching 500 mAh capacity batteryhttps://graphenemg.com/gmg-achieves-500mah-graphene-aluminium-ion-battery-prototype-in-pouch-cell-format/Sep 2023Battery Technology Readiness Level (BRTL) 4 reachedhttps://graphenemg.com/gmg-achieves-500mah-graphene-aluminium-ion-battery-prototype-in-pouch-cell-format/Nov 2023Rio Tinto and GMG Partnership Video Launchedhttps://graphenemg.com/rio-tinto-gmg-battery-partnership-video-launch/Dec 2023Commissioning of modular Graphene Production Planthttps://graphenemg.com/graphene-manufacturing-group-commissions-modular-graphene-production-plant/Feb 20241000 mAh Capacity Reachedhttps://graphenemg.com/gmgs-graphene-aluminium-ion-battery-1000-mah-capacity-reached-and-next-steps-toward-commercialisation/Mar 2024Graphene Manufacturing Group Secures AU$2 million Funding Grant from Queensland Government for Battery Pilot Planthttps://graphenemg.com/graphene-manufacturing-group-secures-au2-million-funding-grant-from-queensland-government-for-battery-pilot-plant/Aug 2024GMG's Graphene Aluminium-Ion Battery: Progress Update and Next Steps Toward Commercialisationhttps://graphenemg.com/gmgs-graphene-aluminium-ion-battery-progress-update-and-next-steps-toward-commercialisation/Mar 2025GMG's Graphene Aluminium-Ion Battery: Collaboration with World Leading USA Battery Innovation Centre and Next Steps Toward Commercialisationhttps://graphenemg.com/gmgs-graphene-aluminium-ion-battery-collaboration-with-world-leading-usa-battery-innovation-centre-and-next-steps-toward-commercialisation/ About BIC:BIC is a collaborative initiative designed to incorporate leadership from renowned universities, government agencies, and commercial enterprises. BIC is a public-private partnership and a not-for-profit organization focusing on the rapid development, testing and commercialization of safe, reliable and lightweight energy storage systems for defense and commercial customers. BIC is a unique organization that has been leading battery cell development for world leading battery companies for over 10 years and has carried out over 500 battery development projects.About GMGGMG is an Australian based clean-technology company which develops, makes and sells energy saving and energy storage solutions, enabled by graphene manufactured via in house production process. GMG uses its own proprietary production process to decompose natural gas (i.e. methane) into its natural elements, carbon (as graphene), hydrogen and some residual hydrocarbon gases. This process produces high quality, low cost, scalable, 'tuneable' and low/no contaminant graphene suitable for use in clean-technology and other applications.The Company's present focus is to de-risk and develop commercial scale-up capabilities, and secure market applications. In the energy savings segment, GMG has initially focused on graphene enhanced heating, ventilation and air conditioning ("HVAC-R") coating (or energy-saving coating) which is now being marketed into other applications including electronic heat sinks, industrial process plants and data centres. Another product GMG has developed is the graphene lubricant additive focused on saving liquid fuels initially for diesel engines.In the energy storage segment, GMG and the University of Queensland are working collaboratively with financial support from the Australian Government to progress R&D and commercialization of graphene aluminium-ion batteries ("G+AI Batteries"). GMG has also developed a graphene additive slurry that is aimed to improve the performance of lithium-ion batteries.GMG's 4 critical business objectives are:Produce Graphene and improve/scale cell production processesBuild Revenue from Energy Savings ProductsDevelop Next-Generation BatteryDevelop Supply Chain, Partners & Project Execution CapabilityFor further information please contact:Craig Nicol, Chief Executive Officer & Managing Director of the Company at craig.nicol@graphenemg.com, +61 415 445 223Leo Karabelas at Focus Communications Investor Relations, leo@fcir.ca, +1 647 689 6041www.graphenemg.comNeither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this news release.Cautionary Note Regarding Forward-Looking StatementsThis news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends", "expects" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or will "potentially" or "likely" occur. This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, statements regarding the lower cost to produce GMG G+AI batteries, expectations for GMG G+AI batteries in respect of charging time, energy density, life cycle, safety, thermal runway risk and the need for a thermal management system when development is completed, that the new hybrid electrolyte is chloride free and non-corrosive, that the cathode and anode technology employed enables very fast and stable charging, that GMG G+AI batteries provide significant cost and weight savings relative to copper, that G+AI batteries can achieve over 150 Wh/kg charged over 1 hour and 75 Wh/kg when charged over 6 minutes following further development of cathode, anode, electrolyte and component weights, that G+AI batteries will progress to BTRL 7 and 8, that the timeline for the battery cell roadmap is achievable, that a range of global companies in a variety of industries will be interested in working with GMG, that the battery pack design will be plastic and which offers weight, cost and complexity advantages to a metal case and increased energy density, expectations for the lack of a thermal management system or fireproofing precautions, expectations for material and manufacturing costs, expectations for sales of LTO batteries, expectations for G+AI batteries being substitutable for LTO batteries at lower cost, expectations that G+AI batteries are viable 12V starter battery replacements and the rationale therefor and the advantages of pouch design for aerospace weight requirements and constrained dashboards of autonomous robots.Such forward-looking statements are based on a number of assumptions of management, including, without limitation, assumptions that GMG G+AI batteries can be produced at lower cost, as to charging time, energy density, life cycle, safety, thermal runway risk and the need for a thermal management system for G+AI batteries, the speed and stability of charging, that G+AI batteries will progress to BTRL 7 and 8, that a range of global companies in a variety of industries will be interested in working with GMG, that the battery pack design will be plastic and offer weight, cost and complexity advantages to a metal case and increased energy density, that the service agreement with the BIC will enable the Company to optimize its cell design and battery manufacturing equipment, and that the Company will be able to meet its overall timeline on the battery cell roadmap. Additionally, forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of GMG to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: that GMG G+AI batteries cannot be produced at lower cost, or any of the assumptions as to charging time, energy density, life cycle, safety, thermal runway risk and the need for a thermal management system for G+AI batteries can not be achieved, G+AI batteries do not offer expected speed and stability of charging, that G+AI batteries will not progress to BTRL 7 and 8, that a range of global companies in a variety of industries will not be interested in working with GMG, that the battery pack design will not be plastic and not offer weight, cost and complexity advantages to a metal case and increased energy density, that the Company will not be able to optimize the electrochemical behaviour of the pouch cell through laboratory experimentation or at all, that the Company will not be able to meet its overall timeline on the battery cell roadmap, that the service agreement with the BIC will not enable the Company to optimize its cell design and battery manufacturing equipment and the risk factors set out under the heading "Risk Factors" in the Company's annual information form dated November 04, 2025 available for review on the Company's profile at www.sedarplus.ca.Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.[1] Lithium Titanate Oxide Battery Market Size, Share & 2030 Growth Trends Report[2] LFP: https://www.evlithium.com/catl-battery-cell/catl-150ah-lifepo4-battery-cell.htmlLNMC: https://keheng-battery.com/product/catl-nmc-3-7v-151ah-high-energy-density-battery-for-ev/LTO: https://www.global.toshiba/ww/products-solutions/battery/scib/product-next/product/cell/high-power.htmlLead Acid: https://www.altronics.com.au/p/s4530-12v-3.5ah-sealed-lead-acid-sla-battery/?srsltid=AfmBOoqZGMEIsX__YYOuRLC3nvYDFtNkf35qZYuYeoh3ACf4wrrOLISD[3] https://findingspress.org/article/21459-impact-of-charging-rates-on-electric-vehicle-batt[4] High-power type cells | SCiB™ Rechargeable battery | Toshiba[5] https://www.ritarpower.com/industry_information/The-Price-of-50-kWh-Lithium-Ion-Batteries-A-Comprehensive-Analysis_297.html#:~:text=Lithium%20Titanate%20(LTO)%20Batteries%3A,cost%20between%20%2440%2C000%20and%20%2460%2C000.[6] https://www.grepow.com/blog/battery-energy-density.html[7] Lithium Titanate Oxide Battery Market Size, Share & 2030 Growth Trends ReportTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/278044 Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
CMS (867.HK/8A8.SG): Innovative Drug Oral JAK1 Inhibitor Povorcitinib Has Been Included in the List of Breakthrough Therapeutic Drugs in China ACN Newswire

CMS (867.HK/8A8.SG): Innovative Drug Oral JAK1 Inhibitor Povorcitinib Has Been Included in the List of Breakthrough Therapeutic Drugs in China

SHENZHEN, Dec 15, 2025 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS”, or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for an independent listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement of the Company dated 22 April 2025 for details), has obtained the relevant licensing rights to the innovative oral JAK1 inhibitor povorcitinib (proposed English generic name: Povorcitinib Phosphate Tablets) (“povorcitinib” or the “Product”), which has been included in the list of Breakthrough Therapeutic Drugs by the Center for Drug Evaluation of the National Medical Products Administration of the People’s Republic of China (“NMPA”), with a proposed indication for adult patients with non-segmental vitiligo. This certification has the potential to accelerate the development and review process of the Product.Povorcitinib is a selective oral small-molecule JAK1 inhibitor, with compound and use patents in certain countries/regions in the Territory. Currently, povorcitinib is in Phase 3 clinical trials for non-segmental vitiligo, moderate to severe hidradenitis suppurativa (HS) and prurigo nodularis in several countries outside China. A Phase 2 clinical trial for the treatment of asthma is also ongoing.In March 2023, Incyte announced that povorcitinib met the primary endpoint in a global multi-center Phase 2b clinical trial for non-segmental vitiligo. Results showed that after 24 weeks of treatment, compared with vehicle, total body repigmentation of patients treated with povorcitinib once daily was significantly improved. Furthermore, according to the extended Phase 2b trial, longer-term use of povorcitinib demonstrated further improvement in total body and facial repigmentation with a favorable tolerability profile[1]. In August 2025, Dermavon received the drug clinical trial approval notice issued by NMPA to conduct clinical trials of povorcitinib for the treatment of non-segmental vitiligo and other indications. Dermavon has initiated the clinical development of the Product in China and may consider further initiating clinical development of povorcitinib in China for the treatment of skin-related diseases such as HS and prurigo nodularis in the future.Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million[2]. Currently, therapeutic options for vitiligo are limited, and the condition is difficult to treat, especially for patients with moderate to severe extensive vitiligo. If approved in China, povorcitinib could provide a differentiated treatment option for patients with non-segmental vitiligo.The Product's inclusion in the list of Breakthrough Therapeutic Drugs is expected to accelerate its development and review process in mainland China. If approved for marketing in China, the Product has the potential to synergize with Dermavon’s commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream) and the innovative drug currently under New Drug Application (NDA) review ruxolitinib phosphate cream, helping the product to quickly realize its clinical and commercial value and benefit more patients with skin diseases. Furthermore, if approved, the Product, together with topical ruxolitinib phosphate cream, will provide vitiligo patients with differentiated and comprehensive treatment options.The Group, through a subsidiary of Dermavon entered into a Collaboration and License Agreement (the “License Agreement”) for povorcitinib on 31 March 2024 with Incyte, obtaining an exclusive license to research, develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights of povorcitinib in the Territory other than Mainland China to the Group (excluding Dermavon and its subsidiaries).About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference:1. Results from a global multi-center Phase 2b clinical trial of the product for non-segmental vitiligo indication can be found on the Incyte official website: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-data-phase-2b-study-evaluating-povorcitinib2. Datas are from the China Insights Consultancy (CIC) reportCMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More

希迪智駕招股進行中:構築智能駕駛產業化底座 多場景落地打開成長空間

香港, 2025年12月15日 - (亞太商訊 via SeaPRwire.com) - 在全球新一輪科技革命與產業變革加速演進的背景下,智能駕駛產業正迎來爆發式增長,作為深耕該領域的核心力量,希迪智駕(3881.HK)于12月11日正式啟動招股程序,目前相關工作正有序推進中,公司赴港上市進程已進入最後衝刺階段,距離登陸港股資本市場僅一步之遙。全面技術體系:從算法到系統工程的縱深掌控自動駕駛作為集感知、決策、控制、調度、通信於一體的複雜系統工程,對企業的技術掌控力與全鏈條集成能力提出極高要求。自創立以來,希迪智駕便堅持技術自主化,通過組建專業研發團隊,體系化地開發了高效算法、軟件、子系統及場景模塊,覆蓋自動駕駛各個方面,從而開發出行業領先的產品及解決方案。在感知與算法層面,希迪智駕融合多元傳感技術與深度學習算法,實現全天候高魯棒性的目標識別與環境理解,適應礦區揚塵、震動干擾、交通交互等多樣化環境。在決策和控制層面,希迪智駕開發了基於場景驅動的路徑規劃機制與多車協同調度系統,支持多車動態調度、穩定運行。在系統工程層面,公司搭建了遠程接管平台、車載計算系統、V2X通訊模塊與調度中台,形成端到端的全閉環部署能力。希迪智駕目前在中國擁有513項專利申請和362項註冊專利,其中包括170項發明專利、107項實用新型專利和85項外觀設計專利,覆蓋算法、調度邏輯等關鍵核心領域,充分體現了其核心技術的深度與廣度。依託全面自主技術體系,希迪智駕在確保安全的前提下,不僅能快速迭代產品、降本增效,也使其在快速發展的產業環境中,擁有對技術命脈的掌控權與更強的成本控制能力,從而完成項目交付與升級閉環,在行業內建立起深厚的技術護城河。場景落地夯實商業根基 為後續增長提供強勁動力以技術為基石,希迪智駕深耕B端核心場景,在商用車、礦區、港口、園區等領域構建起顯著競爭優勢,憑藉成熟的量產能力與標杆客戶背書,實現商業化落地與規模化營收的雙重突破。在國內市場,希迪智駕打造了多個具有行業里程碑意義的標杆項目,贏得戰略合作夥伴的廣泛信任。在自主採礦領域,公司於江蘇省句容市為TCC交付了中國首個完全無人駕駛純電採礦車隊,該項目同時也是全國首個通過NIM認證的自主採礦項目,作業效率遠超傳統人工採礦;在西北區域,其打造的有人與無人駕駛採礦混編車隊,規模位居中國(含香港、澳門及臺灣)第一;在河南鄭州,自主研發的全無人駕駛採石場系統實現與挖機的協同作業,成為行業技術應用新標杆。在V2X領域,自2018年自主研發的V2X設備實現初步商業化以來,希迪智駕持續突破,創新推出V2X+主動式公交信號優先系統,並在重慶市兩江新區建設最大的國家級車聯 網先導區之一的過程中發揮了關鍵作用。在智能感知領域,公司成為業內首批為列車交付前裝量產自主感知系統的企業之一,相關成果獲業界廣泛認可。商業化成果的持續落地轉化為堅實的經營數據。截至2025年6月30日,希迪智駕已向客戶交付414輛(套)自動駕駛礦卡(系统),同時收到647輛(套)自動駕駛礦卡(系统)的指示性訂單,訂單儲備充足,為後續增長提供強勁動力。依託國內項目的成功經驗,希迪智駕積極推進全球化佈局,將成熟的業務模式複製至海外市場,在多個海外地區建立穩固的客戶關係與市場根基,成功簽署多個海外項目,全球化發展戰略成效顯著。從自動駕駛底層技術突破到場景級產品集成,希迪智駕構建出一條極具技術深度與商業廣度的成長路徑。通過「自研+集成+協同」的技術體系,公司不僅跑通了多場景落地,也建立起面向未來的持續演進機制。在港上市後,公司將充分借助國際資本市場的多元資源優勢,繼續深化技術創新,積極拓展全球應用場景邊界,在智能駕駛產業的高速發展中,持續以技術突破賦能產業升級,以創新活力引領行業前行,其長期增長潛力值得高度期待。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
雲頂新耀發佈2030戰略規劃 管理層及主要股東增持超3800萬港元股份 ACN Newswire

雲頂新耀發佈2030戰略規劃 管理層及主要股東增持超3800萬港元股份

香港, 2025年12月15日 - (亞太商訊 via SeaPRwire.com) - 雲頂新耀(HKEX 1952.HK)發佈公司2030發展戰略。受戰略發佈提振,公司股價當日整體表現強勁,盤中一度觸及48.54港元的階段高點。截至當日收市,雲頂新耀股價報46.88港元,上漲4.55%,股價全天維持在相對高位運行,顯示市場反應積極。市場認為,當日股價的強勢表現,既反映了投資者對公司中長期戰略方向的認可,也與此前管理層及主要股東釋放的信心信號密切相關。此前於12月12日,雲頂新耀對外披露董事及主要股東增持公司股份的相關公告,多位管理層成員通過公開市場合計增持公司普通股846,659股,涉及總金額超過3,800萬港元;同時,主要股東康橋資本亦承諾將在未來三至六個月內,在視市場情況及符合法律監管要求的前提下,進一步增持公司股份。相關舉措被視為管理層及核心股東對公司長期發展前景的明確表態。雲頂新耀2030戰略明確提出以「BD合作+自研」雙輪驅動,實現商業化創造確定性價值、自研創造成長性價值。公司將持續鞏固核心治療領域優勢,推進創新藥研發和商業化,打造可持續增長的全球化創新型生物制藥企業。公司聚焦腎科、自身免疫、急重症、心血管及眼科等核心方向,通過引進創新資產與自主研發並行推進,到2030年形成高價值產品組合,並拓展其他藍海領域的大單品。商業化平台建設方面,公司已布局三款商業化產品,並著力建立全渠道商業化體系及藥品全生命周期商業化能力。到2030年,公司計劃實現收入規模超過150億元人民幣,其中現有管線銷售收入約90億元,新引進管線銷售收入約60億元,並探索潛在對外授權(License-out)收入;年複合增長率預計在2025-2030年超過50%,2030年後保持超過15%。同時,商業化產品數量將提升至20款以上,包括耐賦康®、維適平®、依嘉®、頭孢吡肟-他尼硼巴坦及樂瑞泊®(萊達西貝普)等。研發平台方面,公司以擁有全球權益的自研mRNA平台為基礎,持續推進現有管線,同時通過引進及生態孵化潛力平台拓展研發能力。到2030年,在核心平台mRNA in vivo CAR-T和mRNA腫瘤疫苗平台基礎上,擴展至其他高潛力平台(比如siRNA、抗體等),進一步強化核心治療領域研發實力。全球化能力建設方面,公司啟動全球化戰略,推進全球化的注冊及臨床開發能力建設,同時逐步自建歐美及新興市場商業化體系,盡快實現「海外授權+商業化」的雙引擎驅動增長,加快國際化發展步伐。值得一提的是,作為新橋生物的第一大股東(持股約16%)及重要戰略投資者,雲頂新耀還計劃與新橋生物深度協同,發掘優質資產,加強全球化研發能力建設,並通過創新藥商業化整合平台及「BD合作+自研」雙輪驅動模式,進一步拓展全球商業化及研發注冊能力。同時借助新橋生物在不限治療領域的全球化產業資源、團隊及頂尖人才,實現雙方優勢互補。雲頂新耀董事會榮譽主席、康橋資本首席執行官傅唯先生表示:「雲頂新耀發佈的2030戰略充分體現了公司在創新藥研發、商業化和全球化布局上的清晰規劃與前瞻性,展示了持續創造價值的能力。自2017年成立以來,公司通過授權引進(license-in)引入創新資產,建立了堅實的基礎,完成在香港交易所IPO,並依靠『雙輪』驅動戰略,聚焦藍海領域,打造卓越商業化平台並完善研發和生產能力,為公司未來發展奠定了堅實基礎。康橋資本將充分發揮全球產業資源和生態網絡優勢,與公司共享戰略與運營經驗,支持核心管線和研發平台的持續發展。作為主要股東,我們也通過增持股份進一步表達對公司長期發展前景的認可和支持。期待公司在未來持續引領創新藥研發與商業化發展,打造全球領先的綜合性生物制藥企業。」雲頂新耀董事會主席吳以芳先生強調:「2030戰略標志著雲頂新耀邁向全球生物制藥前沿的重要里程碑。未來五年,公司將聚焦『BD合作+自研』雙輪驅動,依托科學與市場洞察,推動戰略領域形成N+X產品組合,把握藍海大單品機遇。公司計劃通過已經建立的BD能力和康橋生態,每年引進3-5個中後期重磅產品,依托自身精幹高效的商業化團隊實現每個產品醫保後三年銷售達峰。未來五年,公司計劃引進20個以上的高值資產,為2030年貢獻收入60億,在2035年實現大約300億的收入貢獻。在自研方面,公司將持續推進創新藥自主研發平台建設,強化核心治療領域研發能力。同時,公司近期與海森生物簽署的商業化服務協議及授權許可協議,將充實後期管線布局、提升商業化平台運營效率,並助力心血管及相關領域業務拓展。未來,公司將持續推動管線拓展、商業化能力建設及全球研發佈局,不斷提升雲頂新耀在全球創新藥領域的綜合競爭力。在商業化現金流持續改善及充裕現金儲備的有力支撐下,公司將加快戰略落地,穩步邁向千億市值計劃的目標,為更多患者帶來高價值的創新治療選擇。」雲頂新耀首席執行官羅永慶先生表示:「通過深化『雙輪驅動』戰略,雲頂新耀正加速邁向全球領先的生物制藥公司。公司已建立以『科學及商業洞察驅動的醫學、准入、市場、銷售一體化協同』為核心的商業化體系,並持續強化平台能力建設,推動核心產品穩健增長。作為一款慢病用藥,耐賦康®在上市後的首個完整商業化年度,依靠不到200人的一線銷售團隊,今年前3季度銷售額已突破10億元成為行業最佳實踐之一,充分驗證了公司成熟且可複制的商業化能力。基於此,公司將把在腎科及抗感染領域積累的商業化體系與經驗,拓展至自身免疫、眼科、急重症及心血管等治療領域。科學及商業洞察也是研發的戰略出發點,我們將同時加速推進自研mRNA In vivo CAR-T平台及mRNA腫瘤疫苗平台的臨床開發進程。在2030戰略指引下,雲頂新耀將持續聚焦中國及全球尚未滿足的醫療需求,不斷提升全球創新藥競爭力,為更多患者帶來高價值創新治療選擇。」整體來看,雲頂新耀此次發佈的2030戰略,不僅系統規劃了未來發展的業務路徑,更通過管理層與主要股東的主動增持行動,體現了內外一致的戰略認同與長期信心。展望未來,在「雙輪驅動」戰略的持續引領下,雲頂新耀將繼續鞏固在核心治療領域和創新藥研發上的優勢,穩步邁向可持續增長的全球化生物制藥企業目標,成為全球領先的綜合性生物制藥公司。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
Indonesia’s KAI Launches Farmer-Trader Train, Expands Facial Recognition Tech Ahead of 2025/2026 Holiday Travel Surge ACN Newswire

Indonesia’s KAI Launches Farmer-Trader Train, Expands Facial Recognition Tech Ahead of 2025/2026 Holiday Travel Surge

JAKARTA, Dec 15, 2025 - (ACN Newswire via SeaPRwire.com) - Indonesia's state-owned railway operator PT Kereta Api Indonesia (KAI) has rolled out two major initiatives aimed at strengthening national mobility and accelerating its digital shift: the launch of the Farmer and Trader Train on the Merak Commuter Line, and the expansion of face recognition boarding technology ahead of the 2025/2026 Christmas and New Year travel season.Farmer-Trader train to facilitate the movement of agricultural goods, processed food, and small-scale merchandise by providing dedicated cargo space within a commuter railway environment.KAI said the programs reflect its commitment to inclusive transport services while enhancing operational efficiency and environmental performance — moves that align with international railway modernization trends.A special passenger train featuring oversized windows and often a large glass roof (sunroof) to provide unobstructed, wide-angle views of the passing scenery, turning the journey itself into a scenic experience."KAI is committed to building a rail ecosystem that supports grassroots economies while adopting technologies that meet global service standards," said KAI President Director Bobby Rasyidin. "These initiatives reinforce railways as an inclusive, efficient, and sustainable mode of public transport."New Farmer–Trader Train Strengthens Local Product DistributionEffective 1 December 2025, KAI began operating the Farmer and Trader Train on the Merak–Rangkasbitung corridor in Banten Province. The service is designed to facilitate the movement of agricultural goods, processed food, and small-scale merchandise by providing dedicated cargo space within a commuter railway environment.The rolling stock was fully redesigned by Balai Yasa Surabaya Gubeng, KAI's technical workshop, which modified the interior layout, baggage sections, loading–unloading access points, and safety signage to meet the needs of micro and small enterprises."The train has been engineered by our in-house experts to ensure safe, orderly, and convenient goods movement without disrupting passenger flow," continued Rasyidin.The service operates under a government-funded Public Service Obligation (PSO) scheme with a flat fare of Rp3,000, allowing up to two cargo units per user. It is attached to 14 daily Commuter Line services and stops at 11 stations across coastal and agricultural areas.On launch day, 95 customers used the service, carrying agricultural produce, snacks, and handicrafts for markets in Serang, Cilegon, and Merak. KAI expects the service to reduce traders' reliance on road-based logistics and shift more local supply chains onto rail.Rasyidin said the initiative strengthens regional economic resilience: "Reliable logistics access for small producers is fundamental to local economies. This service opens a more predictable distribution channel for farmers and traders."Facial Recognition Technology Boosts Efficiency, Cuts WasteKAI is also expanding its facial recognition boarding system to improve passenger processing and reduce paper usage in major stations.KAI VP Public Relations Anne Purba, explains, between January and October 2025, the feature recorded 9.29 million uses, cutting ticket paper consumption by 23,245 rolls, equivalent to Rp341 million in savings. Since the system debuted in 2023, it has been used by 19.4 million passengers, contributing significantly to KAI's environmental and cost-reduction goals."Facial recognition shortens boarding time and significantly reduces paper waste, supporting more environmentally responsible operations," Purba said.The technology is now available in 22 stations, with wider deployment planned ahead of peak holiday travel to reduce queues and streamline passenger flow.Purba underscored the strategic value of automation: "Digitalization is not just innovation—it is increasingly essential to managing national mobility at scale. This system helps maintain operational stability when travel demand peaks."Holiday Ticket Sales Climb, Discounts ExpandedDemand for the year-end holiday period—18 December 2025 to 4 January 2026—continues to rise. As of 26 November, KAI had sold 629,060 tickets, or 21.15% of the roughly 3 million seats available.To support affordability and smooth travel, KAI is offering 30% discounts for 156 regular services and 26 additional economy-class trains, totaling 1.5 million discounted seats valid from 22 December to 10 January.Purba said higher mobility is expected across Java and Sumatra: "We are preparing large capacity and fare incentives to ensure safe, orderly, and accessible travel throughout the holiday season."Inclusive and Technology-Driven Mobility for IndonesiaBy combining inclusive rural-focused services with large-scale digital transformation, KAI aims to bring Indonesia's rail sector closer to global standards of accessibility, efficiency, and sustainability."Our strategy aligns with international efforts to build modern public transport systems that deliver broad social and economic impact," Purba concluded.For More Information, please contact:Anne PurbaVP Public RelationsPT Kereta Api Indonesia (Persero)Source: PT Kereta Api Indonesia (Persero), https://www.kai.id Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
TransNusa Secures 19 Scheduled Flight Routes Within Three Years of Operations ACN Newswire

TransNusa Secures 19 Scheduled Flight Routes Within Three Years of Operations

TransNusa Launched 11 International Routes in 3 YearsIndonesia-based PT TransNusa Mandiri Aviation grows a strong brand with expansion focusing on international routesTransNusa focuses on international tourism island destinations to offer domestic and foreign tourists increased air connectivityTransNusa introduces four new domestic scheduled direct flights to boost connectivity from Bali to Lombok and Bima as well as between renowned diving destinations Manado to Sorong and Sorong to Timika, world’s largest gold mining islandJAKARTA, Dec 15, 2025 - (ACN Newswire via SeaPRwire.com) - TransNusa has successfully launched four new domestic routes today, securing 19 routes in total within three years of operations.TransNusa Group CEO, aviation veteran, Datuk Bernard Francis, known for his acute, unique and out-of-the-box turnaround and change management strategies, led TransNusa towards a secure yet bold growth pattern using a customized business model, which was specifically developed to suit the changing market demand after the onslaught of the pandemic.“What we envisioned for TransNusa was to build an Indonesian-based airline with strong fundamentals. Today, thanks to our hard working and diligent team, the TransNusa brand has grown to resonates confidence and trust,” said Datuk Bernard, adding that TransNusa’s shareholder, China Aircraft Leasing Group Holdings Limited (CALC) and business partners also played a large role in helping build TransNusa into the strong brand it is today.Within 6 months of its operations, TransNusa launched its first international route between Jakarta and Kuala Lumpur, followed by three additional international routes in that same year, including Singapore and China.TransNusa also implemented a milestones as well as initiated and developed new domestic routes, such as the Bali-Manado route.In addition, TransNusa the first Indonesian airline to operate regular scheduled international flights into Guanzhou from three destinations in Indonesia.Datuk Bernard said the primary factor in the successful growth of TransNusa, in the last three years, was their goal to implement a lasting and impactful change around not just the organisation and its people but also its business model and operations.“In TransNusa, a 100% change is not possible overnight, whereas a 5% change in a moderate manner is not only more feasible but allows for a lasting change,” said Datuk Bernard, explaining that it was that principal which has been the backbone of TransNusa's operations and growth.On the new domestic route launches, Datuk Bernard said that TransNusa hopes to provide increased connectivity and travelling options to domestic and international tourists.“We would like to play our part in boosting and increasing air connectivity within Indonesia’s internationally renowned tourism island destinations.“Our focus is in increasing direct flight to destinations that are world renowned for its unique and stunning landscape and natural offerings,” said Datuk Bernard.DATUK BERNARD FRANCIS… TransNusa's team and business partners contributed to the growth of the airline and it’s brand.Flight DetailsTransNusa’s flight from Bali to Lombok will operate two times daily beginning Monday, December 15. The TransNusa flight will depart Bali from the Denpasar International Airport at 07.30am and arrive in Lombok International Airport at 07.55am, with the return flight departing Lombok at 08.25am and arriving in Bali at 09.05am. The second TransNusa flight will depart Bali at 15.55pm and arrive in Lombok at 16.50pm, with the return flight departing Lombok at 17.20pm and arriving in Bali at 18.05pm.“We will increase the frequency of the scheduled flights for the Bali-Lombok route to three times daily on December 21.” Said Datuk Bernard.The third scheduled flight will depart Bali at 18.55pm and arrive at Lombok at 19.35pm. The scheduled flight from Lombok will depart at 20.00pm and arrive in Bali at 20.25pm.Meanwhile, TransNusa’s flight from Bali to Bima will also begin on Monday, December 15.“For the first week, we will operate one scheduled flight from Bali to Bima on Monday, Wednesday, Friday and Sunday.“Starting December 22, TransNusa will operate daily scheduled flights from Bali to Bima,” said Datuk Bernard, adding that the flight will depart Bali from the Denpasar International Airport at 09.35am and arrive at 10.35am at the Sultan Muhammad Salahuddin Airport in Bima.The return flight will depart Bima’s Sultan Muhammad Salahuddin Airport at 11.00am and arrive at Bali’s Denpasar International Airport at 12.10pm.Meanwhile, TransNusa’s schedule flight from Sorong to Timika will operate four times weekly on Monday, Tuesday, Thursday and Saturday.The flight, which will also begin on December 15, will depart Sorong from the Domine Eduard Osok International Airport at 10.50am and arrive in Timika’s Mozes Kilangin Airport at 12.10pm. The return flight will depart Timika at 12.40pm and arrive in Sorong at 14.00pm.On the much sought-after Manado-Sorong route, Datuk Bernard said that TransNusa’s will operate its scheduled flight from Manado to Sorong four times weekly.The scheduled flight from diving haven Manado will operate on Monday, Tuesday, Thursday and Saturday. The flight will depart Manado’s Sam Ratulangi International AIrport at 08.00am and arrive in Sorong’s Domine Eduard Osok International Airport at 10.20am. The return flight will depart Sorong at 14.30pm and arrive in Manado at 14.50pm.TransNusa, A Short HistoryThe 3-year old TransNusa, led by aviation expert and veteran, Datuk Bernard, made waves in the aviation industry with its unique domestic and international business development and growth strategy.Within just 6 months of operations, in 2023, the airline, known then as a new player with new rules, launched its first international route between Jakarta and Kuala Lumpur, followed by the launch of scheduled flights between Jakarta and Singapore.TransNusa, which established itself as a Premium Service Carrier, made headlines in Malaysia, Singapore, China and around the world with news of being the first airline in Indonesia to introduce new exciting routes. In 2023, during its first year of operations, TransNusa became the second Indonesian airline to receive approval to fly to China. In 2024, TransNusa became the first in the world to develop and introduce a new domestic route connecting Bali and Manado. In October 2025, TransNusa added yet another milestones by becoming the first Indonesian airline and second airline in the world to launch scheduled flights from Manado to Guangzhou, China.Media Contact:Trina Thomas RajMobile: +6012 4992672E-mail: trina@myqaseh.org Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
國資護航+技術壁壘+優質保薦 華芢生物(02396.HK)PDGF管線直指18A賽道確定性價值 ACN Newswire

國資護航+技術壁壘+優質保薦 華芢生物(02396.HK)PDGF管線直指18A賽道確定性價值

香港, 2025年12月15日 - (亞太商訊 via SeaPRwire.com) - 12月12日,華芢生物-B(02396.HK)正式開啟招股,公司擬全球發售1764.88萬股股份,其中香港發售股份176.50萬股,國際發售股份1588.38萬股,附帶264.72萬股超額配股權,招股期至12月17日,最高發售價51.00港元,中國生物制藥領域也將迎來重磅IPO。據悉,華芢生物深耕傷口癒合領域,在糖尿病足(糖足)領域取得突破性進展,精准卡位老齡化及糖尿病年輕化萬億級剛需市場。依託青島高科(嶗山區財政局全資控股的國資平台)的產業資源整合能力與政策協同優勢,疊加自主搭建的"蛋白+核酸"雙技術平台及覆蓋14個適應症的差異化管線佈局,以及行業頂尖高管團隊加持,為港股市場投資者構築起抵禦18A生物科技企業高風險的安全邊際。市場普遍將其視為繼寶濟藥業之後又一具備高成長潛力的港股18A標的——不僅擁有扎實的臨床進展和清晰的商業化路徑,更兼具稀缺性與確定性,有望成為下一個被資本市場深度挖掘的價值明星。銀髮浪潮疊加年輕化趨勢:糖足治療剛需市場再擴容據國家統計局數據,全國60周歲及以上人口達3.1億(占總人口22.0%),其中65歲以上人群占比突破15.6%。老齡化加速催生糖尿病防控壓力,而與此同時,糖尿病年輕化趨勢正進一步擴大患者基數,形成"銀髮群體為主、青年群體補充"的雙重市場增量。弗若斯特沙利文報告顯示,我國糖尿病患者約1.4億,四分之一的糖尿病患者會在某個階段發展為糖足,2024年中國的糖足患病人數為840萬人。而當前GLP-1類減肥藥(如司美格魯肽)因減重效果顯著成為"網紅神藥",但其作用機制聚焦於抑制食欲與延緩胃排空,對糖足等血管神經病變類併發症無實質改善。與此同時,術後傷口癒合市場規模同樣超千億,傳統治療手段痛點顯著。在糖足治療領域,已從傳統外科清創轉向生物製劑主導的精准修復時代。中國糖足患者基數龐大,傳統療法(清創+抗生素)因無法解決血管神經病變導致的慢性創面修復障礙,臨床癒合率長期低於50%。PDGF(血小板衍生生長因數)類藥物憑藉其獨特的"血管新生-組織修復"雙效機制,能夠特異性啟動特定受體,促進成纖維細胞增殖與毛細血管生成,顯著加速創面癒合進程,成為千億級慢病管理與術後修復賽道的重磅增長引擎。華芢生物正是瞄準這一藍海市場,向"港股PDGF第一股"發起衝擊。技術突破+醫保減負:核心產品創造多重價值即便處於高研發投入期,華芢生物仍通過自主研發實現關鍵突破——優化核心技術序列並革新生產工藝,構建起差異化競爭優勢。其核心產品Pro-101-1的IIa期數據顯示,可使淺/深二度燒傷癒合時間縮短約7天,較傳統療法效率提升25%,這一突破為患者、醫療體系與醫保基金創造多重價值。對糖足及燒傷患者而言,癒合時間縮短能直接減少住院時長與家庭護理成本,降低因術後恢復導致的誤工、護理人員誤工等間接經濟損失,堪稱"糖尿病足患者的福音";對醫療體系來說,患者住院週期縮短可提高病床周轉率,減少醫療資源佔用,緩解醫護人員工作壓力;對醫保基金而言,治療週期縮短與再治療需求降低,能有效減輕醫保支出負擔,契合當前醫療保障體系降本增效的核心訴求。從技術平台來看,華芢生物以自主搭建的蛋白質藥物技術平台為核心,形成"蛋白+核酸"雙輪創新架構:酵母表達系統通過工藝革新提升蛋白生產效率,雙引擎協同支撐燒傷修復、糖尿病足潰瘍、脫髮治療等核心產品的臨床轉化,同時展現出向腫瘤疫苗、罕見病領域延展的技術潛力,為長期發展奠定技術基礎。國資托底+高管賦能+頂尖平台+強力護航:四重保障化解研發與市場風險生物制藥的研發向來充滿不確定性,一款新藥從實驗室到上市往往九死一生。但在華芢生物這裏,這種風險似乎被巧妙地拆解成了可控變數。在股權與資源端,青島高科產業發展有限公司(嶗山區財政局全資控股的國資平台)作為核心股東,通過持股17.32%(全球發售後相關類別股份)形成長期綁定,其國資屬性為公司在地方醫療資源對接、政策協調中奠定信任基礎,成為連接區域產業生態與研發管線的關鍵紐帶。在管理端,公司獲MNC大廠高管賦能,迎來兩位行業頂尖人才加盟,進一步強化創新發展底氣。其中,苗天祥先生曾是"外資藥企中國掌門人"代表,擁有近30年輝瑞中國工作經歷,曾任輝瑞中國大中華區主席,在財務、企業管理及制藥行業積累深厚經驗,現任華芢生物執行董事兼首席戰略官,負責制定、實施和監督公司整體戰略規劃,為企業把握行業方向、推進研發與市場佈局提供關鍵指導;宋冰女士曾長期任職於頂尖國際投行高盛高華證券,擔任總經理兼首席運營官,在金融投資、企業戰略及資本運作領域具備極強創造力與領導力,現任公司監事會主席,為整體規劃提供建議與監督,助力優化資源整合、提升資本運作效率。兩位核心高管的"組合賦能",與研發團隊技術創新形成合力,讓華芢生物在PDGF藥物研發與市場拓展中具備獨特優勢。在資本端,本次IPO由中信證券擔任聯席保薦人。值得一提的是,中信證券2025年在港股18A生物科技IPO領域表現亮眼,其保薦的其中7個專案均實現首日未破發,映恩生物、勁方醫藥等專案首日漲幅超100%,12月10日掛牌的寶濟藥業更錄得3526.34倍公開發售認購、暗盤一度暴漲超115%的佳績,中慧生物、旺山旺水也分別創下4007.64倍、6238.42倍的超高認購,充分獲得機構及專業投資者認可,為後續二級市場投資者提供堅實信心支撐。在管線端,公司"階梯式"研發管線進一步降低風險。目前,用於治療深二度燒燙傷的產品Pro-101-1,已完成IIb期臨床試驗的統計數據分析,用於治療淺二度燒燙傷的,已完成最後一例患者出組;用於治療糖尿病足潰瘍(糖足)的產品Pro-101-2正處於II期臨床試驗階段。未來,PDGF也有望應用於普通外科、牙科、皮膚科等近20個適應症。就連看似"跨界"的脫髮微針產品Pro-104,也已規劃在2029年提交IND申請。這種"成熟產品貢獻現金流、在研管線儲備未來"的佈局,像極了跨國藥企的經典打法——即便某一管線受挫,也不至於動搖根基。稀缺標的+港股通預期:投資者的優質選擇從市場屬性來看,華芢生物是"小而美"的稀缺標的,當前發行規模適中,流通盤較小,疊加清晰的盈利路徑與高壁壘技術平台,使其具備極強的流動性溢價潛力。市場普遍預期其在滿足市值與流動性條件後有望快速納入港股通,吸引南向資金配置,進一步放大賺錢效應。儘管近期港股市場有6支新股同步發售,資金面承壓,但華芢生物憑藉其純正的18A生物科技屬性,明確的臨床里程碑及國資背景與高管優勢,在年末IPO窗口中脫穎而出。對投資者而言,"國資背書+技術平台+管線梯隊+高管賦能"的組合,讓風險更可量化,契合長期資本對確定性增長的需求。在老齡化加速與創新藥政策紅利共振下,華芢生物以"癒合剛需+技術壁壘+國資護航+高管賦能"構建起獨特價值座標。對於尋求確定性增長的長期資本而言,這家即將登陸港交所的生物制藥新星,或將成為對沖行業波動、捕捉結構性機會的優質標的。其扎實技術與管線積澱更將為港股創新藥板塊注入新動能,推動PDGF藥物行業創新升級,專業投資市場亦在期待其更長期的價值兌現。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
京東工業登陸港交所:業績與品牌雙賦能 長期成長潛力可期 ACN Newswire

京東工業登陸港交所:業績與品牌雙賦能 長期成長潛力可期

香港, 2025年12月12日 - (亞太商訊 via SeaPRwire.com) - 12月11日,中國領先的工業供應鏈技術與服務提供商 - 京東工業(股份代號:7618.HK)正式登陸香港聯合交易所。作為工業供應鏈領域的標杆企業,京東工業的上市不僅是自身發展的里程碑,更為港股市場注入了一支兼具成長力與盈利能力的優質標的。數智化重構價值 財務表現彰顯成長實力作為行業領軍者,京東工業以數智化能力重構工業供應鏈價值。公司通過「太璞」這一「數」(數智)、「實」(商品)結合的全鏈路數智化工業供應鏈解決方案,提供廣泛的工業品供應和數智化供應鏈服務,精准匹配客戶的多元化需求,實現供應鏈效率與成本控制的雙重提升。財務數據是京東工業成長潛力的最直接印證。近年來,公司業績呈現“高增長、高盈利”的雙優態勢,持續經營業務總收入從2022年的人民幣(下同)141億元,穩步增長至2023年的173億元,2024年進一步攀升至204億元,複合年增長率高達20.1%;盈利能力更實現高速穩健增長,2022年,公司錄得经调整淨利潤7.1億元,而2024年大幅攀升至9.1億元,展現出強勁的盈利轉化能力。2025年上半年,公司業績持續釋放,期內公司實現持續經營業務總收入103億元,經調整淨利潤達5.0億元,較上年同期保持高速增長,在複雜的市場環境中展現出穩健的盈利能力與可持續的增長潛力。品牌生態相互協同 構築行業龍頭地位強大的品牌影響力和供應鏈能力為京東工業的發展奠定了堅實基礎。依託JD.com的深厚積澱,公司自成立以來便建立起良好的品牌認可度。值得一提的是,JD.com在2025年《財富》世界500強榜單中位列第44位,作為中國領先的在線零售商,其在商品質量與正品保障上的嚴苛標準,早已成為電商行業的標杆。借助這一優質品牌背書,京東工業成功滲透至多個垂直行業的高價值客戶群體,不僅構建了廣泛的品牌認知,更深化了客戶忠誠度。京東生態系統的協同效應更成為公司的核心競爭力之一。京東工業全面繼承並持續複用京東集團在供應鏈領域的核心優勢,包括一流的技術研發平台、深耕行業的產品知識儲備、覆蓋全國的完善物流服務網絡,以及專業的人才梯隊,這些資源的協同賦能,推動公司在技術創新與服務升級上不斷突破。多重優勢疊加持下,京東工業已確立穩固的行業龍頭地位。截至目前,公司已成為中國MRO採購服務市場的最大參與者,根據灼識諮詢的資料顯示,按2024年的交易額計,公司排名第一,規模為第二名的近三倍。同時,隨著業務向全工業供應鏈領域拓展,公司亦以4.1%的市場份額,成為中國工業供應鏈技術與服務市場的領軍企業。總體而言,京東工業憑藉數智化核心能力、穩健的財務表現及強大的品牌與生態協同優勢,在工業供應鏈這一高增長賽道上構建了深厚壁壘。此次登陸港交所,不僅為公司搭建起更為廣闊的資本運作平台,更標誌著其開啟了與全球投資者共享發展紅利的新征程。展望未來,隨著中國工業數字化轉型的加速推進,京東工業的增長空間有望持續拓寬,長期投資價值值得期待。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
京東工業配售結果出爐:MRO龍頭實力領跑 全鏈條數智化解決方案釋放長期價值 ACN Newswire

京東工業配售結果出爐:MRO龍頭實力領跑 全鏈條數智化解決方案釋放長期價值

香港, 2025年12月12日 - (亞太商訊 via SeaPRwire.com) - 12月10日,京东工业股份有限公司(「京東工業」或「公司」,股份代號:7618.HK)正式公佈全球發售配發結果。公司最終發售價格確定為每股14.10港元,香港公開發售部分反響熱烈,實現60.52倍超額認購,共接收超過7萬份有效申請,最終發售數目為21,121,000股,占全球發售股份總數的約10%;國際配售部分同樣表現亮眼,超額認購倍數約為7.88倍。雙重超額認購的市場反饋,充分彰顯了全球投資者對京東工業商業模式與發展潛力的高度認可。全鏈條解決方案鑄就領先地位 端到端數智化基礎設施賦能龐大客戶群作為中國領先的工業供應鏈技術與服務提供商,京東工業以「太璞」全鏈路數智化解決方案為核心競爭力,構建起「數」(數智)+「實」(商品)深度融合的服務體系,為企業客戶提供覆蓋廣泛的工業品供應及數智化供應鏈服務。通過這一體系,公司能夠有效滿足客戶在保供、降本、增效及合規等多維度需求,推動工業供應鏈領域的數字化變革。憑藉深厚的行業積澱,京東工業確立了市場領先地位,已成為中國MRO採購服務市場的最大參與者,根據灼識諮詢的資料顯示,按2024年的交易額計,公司不僅是中國MRO採購服務市場的龍頭企業,規模接近第二名的三倍,同時也是中國工業供應鏈技術與服務市場的最大服務提供商,市場份額達4.1%,行業標杆地位凸顯。這一地位的背後,是京東工業構建的端到端數智化基礎設施。基於服務千萬企業客戶的實戰經驗,公司打造的「太璞」解決方案,實現了「數」(數智)與「實」(商品)相結合,通過將數智化能力深度賦能客戶,引領企業採購供應鏈的數智化轉型。其核心價值在於踐行「讓數據多跑路,讓商品少跑路」的理念,使供需對接更順暢、匹配更精准、協同更高效,從根本上提升工業供應鏈的整體韌性與敏捷度。二十餘年京東集團供應鏈管理經驗的傳承,為京東工業積澱了深厚的專業知識儲備。在此基礎上,公司不斷迭代自身的供應鏈專業知識,在產品、客戶、垂直行業及供應商等領域實現突破,形成了強大的綜合競爭力。根據灼識諮詢的資料,截至2024年12月31日,公司的SKU數量冠絕中國工業供應鏈技術與服務市場;截至2025年6月30日,SKU數量已增至約8110萬個,2025年6月30日前十二個月內服務重點企業客戶約11100個。高客戶粘性進一步印證其服務價值,2024年重點企業客戶交易額存留率達105.7%,充分體現了客戶對其服務的高度信賴與持續認可。收入與盈利高速增長 數字化浪潮助力打開增長空間受益於行業數字化轉型浪潮及自身核心能力的持續釋放,京東工業近年來業績實現穩步增長。公司持續經營業務總收入從2022年的人民幣(下同)141億元,增長至2023年的173億元,2024年進一步攀升至204億元,複合年增長率達20.1%;從半年期數據看,截至2025年6月30日止六個月,公司持續經營業務總收入達103億元,較上年同期實現顯著增長。同時,公司盈利能力同步實現快速提升,2022年,公司錄得经调整淨利潤7.1億元,而2024年已大幅攀升至9.1億元,2025年上半年,公司延續高增長態勢,经调整淨利潤達5.0億元,較上年同期保持高速增長,展現出強勁的盈利韌性與增長持續性。關於募集資金的用途,京東工業在招股書中已作出明確披露:約35%的募集資金淨額計劃在未來48至60個月內用於於進一步增強公司的工業供應鏈能力;約25%的資金淨額將投入跨地域業務擴張;約30%的資金淨額預留用於潛在戰略投資或收購;剩餘約10%的資金淨額則將用於一般公司用途及補充營運資金,為整體業務的平穩運行築牢保障。一系列清晰詳實的資金規劃,既錨定了業務的持續升級與穩健擴張方向,亦彰顯出公司強勁的發展活力與健康向好的經營態勢。從行業角度來看,中國工業供應鏈市場的數字化滲透率目前仍處於較低水平,存在巨大的提升空間,根據灼識諮詢的資料顯示,中國工業供應鏈市場的數字化滲透率在2024年僅為6.2%,預計到2029年將達到8.2%。數字化滲透率的提高預計將推動工業供應鏈技術與服務市場規模快速增長,由2024年的人民幣0.7萬億元增至2029年的人民幣1.1萬億元,複合年增長率達到9.8%,廣闊的市場空間為京東工業提供了充足的增長動能。京東工業作為工業供應鏈數智化轉型的領航者,既擁有技術賦能的核心優勢,又具備市場領先的規模效應,更手握行業增長的時代機遇。憑藉獨特的業務模式、覆蓋全鏈路的服務能力及持續迭代的創新實力,在港上市後,公司將持續拓展服務邊界與深度,長期增長潛力巨大,有望在實現自身持續成長的同時,為投資者創造長期、穩定的價值回報。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
全鏈條服務+業績高增長彰顯實力 京東工業港交所上市釋放長期價值 ACN Newswire

全鏈條服務+業績高增長彰顯實力 京東工業港交所上市釋放長期價值

香港, 2025年12月12日 - (亞太商訊 via SeaPRwire.com) - 在產業升級、數智化轉型加速及政策支持等多重因素驅動下,工業供應鏈技術正迎來爆發式發展期。作為行業公認的領軍企業,京東工業(7618.HK)憑藉深厚的技術積澱與全鏈條服務能力,於12月11日成功登陸港交所,為工業供應鏈板塊注入一枚優質標的,開啟發展新征程。數智驅動築牢壁壘 全鏈能力構建核心競爭優勢作為中國領先的工業供應鏈技術與服務提供商,京東工業以數智化轉型為核心抓手,致力於為客戶打造保供、降本、增效及合規的全場景解決方案。公司構建了端到端的供應鏈數智化基礎設施,並通過公司廣泛的商品供應、卓越的服務與高效的運營,精准破解工業供應鏈領域諸多共性痛點,構築了強大的核心競爭力。基於這套核心基礎設施打造的「太璞」解決方案,是京東工業「數」(數智)、「實」(商品)結合的全鏈路數智化工業供應鏈的標杆成果,同時,公司採用了輕資產模式搭建高效且可擴展的業務,並通過「太璞」為各行業、各規模的客戶提供跨場景、跨品類的全面工業品供應以及技術與服務,真正實現「大小客戶全覆蓋、全場景需求全滿足」。獨特的價值創造模式為京東工業積累了廣泛且優質的客戶基礎。根據灼識諮詢的資料顯示,截至2025年6月30日前的十二個月內,公司服務約11100個重點企業客戶。2025年上半年,公司的重點企業客戶包括約60%的中國《財富》500強企業及逾40%的在華全球《財富》500強企業,充分印證了市場對其服務能力的高度認可。商品供給能力的廣度與深度,是京東工業的另一核心競爭力。根據灼識諮詢的數據顯示,截至2024年底,按SKU數量計,公司在中國提供最廣泛的工業品供應。具體數據方面,截至2025年6月30日,京東工業提供的工業品SKU數量已達約8110萬個,全面覆蓋80個核心產品類別。截至2025年6月30日前的十二個月內,公司的商品供應源自於由約158000家製造商、分銷商及代理商組成的廣泛的且覆蓋全國的工業品供應網絡,彰顯強勁綜合實力。業績增長強勁 上市募資錨定長遠發展優質的客戶結構與高效的運營模式,推動京東工業的業績實現持續高增長。2022年至2024年,公司持續經營業務總收入從人民幣(下同)141億元穩步增長至204億元,複合年增長率高達20.1%;盈利能力同步提升,經調整淨利潤從2022年的7.1億元大幅攀升至2024年的9.1億元。2025年上半年,公司延續高增長態勢,持續經營業務總收入達103億元,經調整淨利潤為5.0億元,成長韌性凸顯。對於本次上市的募集資金用途,京東工業已制定清晰規劃:約35%將在未來48至60個月內用於強化核心供應鏈能力,進一步夯實技術與服務壁壘;約25%將投入跨地域業務擴張,拓展市場覆蓋邊界;約30%預留用於潛在戰略投資或收購,加速生態整合;剩餘約10%則用於補充營運資金及一般公司用途。這套「強核心、擴邊界、築生態」的資金規劃,為公司長遠健康發展提供了堅實保障。綜合來看,京東工業憑藉數智化技術優勢、全鏈路服務能力、廣泛的客戶基礎及持續的增長潛力,在工業供應鏈升級浪潮中佔據了顯著的先發優勢。此次成功登陸港交所,不僅是公司發展的重要里程碑,更將為其後續成長注入強勁動力。作為工業供應鏈數智化轉型的領軍者,公司的長期投資價值已然凸顯,未來有望在產業升級進程中持續釋放增長活力。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
首隻山水實景表演概念股 印象大紅袍啟動香港公開募股 ACN Newswire

首隻山水實景表演概念股 印象大紅袍啟動香港公開募股

香港, 2025年12月12日 - (亞太商訊 via SeaPRwire.com) - 中國領先的文旅服務企業 – 印象大紅袍股份有限公司(新三板股票代碼:870608)(「公司」或「印象大紅袍」)今日宣佈啟動香港公開發售計劃(「香港公開發售」),計劃於香港聯合交易所有限公司(「香港聯交所」)主板上市(股份代號:2695)。發售詳情印象大紅袍擬全球發售合共36,100,000股股份(視乎超額配股權行使與否而定 ),其中32,490,000股作國際配售(可予重新分配及視乎超額配股權行使與否而定),其餘3,610,000股作香港公開發售,分別位全球發售中發售股份總數的90%及10%售(可予重新分配及視乎超額配股權行使與否而定 ),發售價範圍介乎每股3.47港元至4.10港元。香港公開發售將於2025年12月12日(星期五)上午九時正開始,至2025年12月17日(星期三)中午十二時結束。最終發售價及配發結果將於2025年12月19日(星期五)公佈。股份預計將於2025年12月22日(星期一)在聯交所主板以每手買賣單位為1,000股開始買賣,股份代號為2695。公司擬將全球募集資金淨額用於以下用途:升級標誌性演出《印象‧大紅袍》山水實景演出;創新印象文旅小鎮;取得另一個文化旅遊演出項目;提升品牌形象及擴大業務影響力的宣傳工作;升級票務管理系統及其他軟件;營運資金和其他一般企業用途。興證國際融資有限公司及鎧盛資本有限公司為聯席保薦人。公司主要競爭優勢擁有《印象‧ 大紅袍》的獨家演出權 成功經驗具可複製性公司的標誌性《印象‧ 大紅袍》山水實景演出在福建省乃至全中國都擁有強勢的行業地位。根據弗若斯特沙利文的資料,於2024年,該演出按票房收入計在中國所有旅遊山水實景演出中排名第三。公司背靠強大的股東背景和合作資源,取得《印象‧ 大紅袍》的獨家表演權,這種獨家性為公司提供了顯著的競爭優勢,使公司成為中國旅遊山水實景演出市場及文旅演出市場的無可爭議的市場領導者。《印象‧ 大紅袍》演出以武夷山的自然景色為背景,提供絕美的視覺體驗,同時得益於其被聯合國教科文組織認可的地理位置,武夷山同時擁有文化和自然遺產。這優越的地理優勢與便利的交通相輔相成,結合航空、高速公路和高速鐵路的現代化多維交通網絡,為國內外遊客提供便捷的交通,為公司實現收入增長。《印象‧ 大紅袍》的成功經歷,使公司積累了深厚的文化故事敘述、觀眾互動以及運營卓越的認知,為打造下一款全新節目《月映武夷》奠定重要的成功基石。《月映武夷》演出於2025 年5 月推出,豐富了武夷山市觀看表演演出的選擇,並提供完全不同的戲劇文化體驗。該演出弘揚武夷山朱子文化的傳統中國哲學,表演舞台擁有關鍵的技術特色,被譽為「世界最大的單體結構室內水簾舞台」,已於2025 年5 月1 日獲世界記錄認證公司(World Record Certification Limited) 認證。此部新演出與《印象‧ 大紅袍》山水實景演出形成互補。品牌效應和政府政策背書 建立領先的市場地位福建省擁有豐富的自然景觀和深厚的文化底蘊,當地政府努力增加武夷山與其他主要樞紐城市之間的航班和鐵路連接,並分配資源促進旅遊業發展。福建現場演出市場於2023 年及2024 年分別實現了約485.9%及67.5%的同比增長率。隨著福建作為中國文旅樞紐的聲譽不斷提升,省政府進一步突出「文旅演出+」的概念,促進融合當地文化和標誌性文物景點。公司作為一直深耕福建省武夷山的領先文旅服務企業,《印象‧ 大紅袍》的成功經歷和利好的政府政策背書,充足的文化資源為演出創作者提供豐富的靈感源泉。公司憑藉福建省悠久的文化遺產和多樣的地理風貌的優勢,使其旅遊演出具有潛力、可創造高影響力的價值,成為該地區文旅市場的推手。核心服務聯動 強大協同效應目前公司通過演出及表演服務(《印象‧ 大紅袍》及《月映武夷》)、印象文旅小鎮業務及茶湯酒店業務,產生協同效應,提升整體遊客的體驗,並加強公司在當地文化旅遊市場的競爭優勢。公司戰略性地開發的印象文旅小鎮,主要由武夷茶博園4A級景區、印象建州美食主題街區和武夷茶研習社組成。為了延長遊客觀看演出前的消費鏈,公司把小鎮打造為集「美食餐飲+ 民俗文化+ 商業購物+ 休閒娛樂」於一體。為了豐富遊客的體驗並擴大公司的業務範圍,公司建立的茶湯酒店業務於2021 年盛大開業,其提供以茶為主題的熱浴養生體驗,將大紅袍茶的元素無縫融入賓客的服務之中。整合運營圍繞武夷山大紅袍茶,為公司的三大業務板塊帶來了協同效應。通過整合核心服務組合,公司向武夷山市的遊客提供全面的一站式旅行體驗。遊客可探索印象文旅小鎮,感受當地的茶文化,觀看現場演出,並入住獨特的主題茶湯酒店。多樣活動不僅豐富了遊客的體驗,亦延長了遊客在武夷山的逗留時間,增加了每位遊客的消費額。隨著業務組合的穩步擴大,業務之間的協同潛力可形成良性循環,推動長期穩定增長。提示本次發售將會受到市場和其他條件影響,因此無法保證是否可成功完成發行及完成時間,實際發行規模和具體條件也可能發生變化。本新聞稿僅為印象大紅袍股份有限公司首次公開募股相關資訊之目的而提供,並不構成對該證券的出售要約或購買要約或邀請。也不得在任何國家或其他司法管轄區中要約或出售該證券。如果依據該國家或其他司法管轄的證券法,在註冊或取得資格前進行此種出售要約、要約購買或銷售為非法。本新聞稿並不構成招股章程(包括根據香港法律所定義者),潛在投資者在決定是否投資於公司前,務請細閱公司招股章程內有關公司及建議發售的詳細資料。本新聞稿並未經港交所或香港證券及期貨事務監察委員會審閱或批准。公司股價可能根據香港法例第571W章「證券及期貨(穩定價格)規則」進入穩定期,有關價格穩定詳情及其將如何受到香港法例第571W章「證券及期貨(穩定價格)規則」已在公司於2025年12月12日刊發之招股章程中披露。關於印象大紅袍股份有限公司印象大紅袍股份有限公司(新三板股票代碼:870608)是一家國有文旅服務企業,並於2017年於中國新三板掛牌完成上市。公司業務主要業務分部:(i)演出及表演服務;(ii)印象文旅小鎮業務;及(iii)茶湯酒店業務。其中,公司的標誌性節目《印象‧大紅袍》山水實景演出作為公司的業務的基石,是唯一一個聯合國教科文組織世界自然和文化遺產地內進行的現場演出,也是唯一一個與中國傳統茶文化歷史交織的大型戶外實景演出。於2024 年,《印象‧大紅袍》按票房收入計在中國所有旅遊山水實景演出中排名第三,在所有文化旅遊演出中排名第十1。按文旅演出節目產生的銷售收入計,公司在2024年中國文旅演出市場排名第八1。1根據弗若斯特沙利文的資料本新聞稿由億萬猴財經傳訊有限公司代表印象大紅袍股份有限公司發佈。聯繫方式:Sabrina / Christopher電話:9464 8907 / 5592 6231電郵:sabrinawong@bmonkey.com.hk / christopher@bmonkey.com.hk Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
2026 Hong Kong Export Growth of 8-9%, Sustained AI product demand lays solid foundation for future expansion ACN Newswire

2026 Hong Kong Export Growth of 8-9%, Sustained AI product demand lays solid foundation for future expansion

HONG KONG, December 11, 2025 - (ACN Newswire via SeaPRwire.com) – Hong Kong’s exports are expected to grow by between 8% and 9% in 2026, according to figures releaased today by the Hong Kong Trade Development Council (HKTDC). The forecast forms part of the HKTDC’s annual Export Outlook report and follows on from the city’s better-than-anticipated 2025 export performance.For 2026, this sustained growth is set to be driven by robust demand for AI-related electronics products. According to the findings of the recently-released HKTDC 4Q25 Export Confidence Index, the majority of exporters (53.2%) see rising demand for AI/new technology-related electronic consumer goods as the factor most likely to boost their 2026 business. This is seen as crucial given that the electronics sector, overall, accounts for more than 70% of Hong Kong’s total export value.Heightened uncertainty giving way to greater clarityThese upbeat figures are remarkable given the high year-on-year comparison base from 2025. This is because many exporters sought to frontload orders in a bid to complete shipments before the imposition of the much-anticipated US tariffs.Detailing the upshot of the tariff-related trade upheavals in particular, Irina Fan, Director of HKTDC Research, said: “While 2025 proved to be a year of heightened uncertainty, 2026 should be a year of greater clarity on global trade. With the Chinese Mainland and the US having come to a trade agreement in November, – some four months after many other nations had struck their own deals with the Trump administration – US tariffs are no longer among Hong Kong exporters' three biggest 2026 concerns.”Fan did, however, acknowledge that uncertainties remain ahead. She said that as US imports from different countries are subject to different levels of tariffs, business leaders around the world will be looking to re-organise their activities to optimise any cost advantages.Outlining what this will mean within the Asia-Pacific region, Fan said: “Chinese Mainland exports to the US will be subject to 20% reciprocal tariff rate until November 2026 [1]. This comparatively low additional tariff puts China-based suppliers, many with more mature and highly productive supply chains, on par with their Southeast Asia counterparts, while giving them a significant advantage over any country subject to a higher tariff rate.”Multi-sector expectation of continued export expansionUnderpinning Hong Kong’s anticipated 2026 export expansion are the findings of the HKTDC Export Confidence Index 4Q25, which was also released today. The two key measures of this long-established quarterly metric –the Current Performance Index (51.4) and the Expectation Index (51.9) – have both stayed above the 50-point watershed level, a clear indication that future export growth is expected.Commenting on the findings of the 4Q25 survey, Kenneth Lee, Head of the HKTDC Research’s Special Project and Business Advisory Section, said: “When it comes to expansion plans over the next two-year period, Asia remains very much the focus. For 42.0% of respondents, the Chinese Mainland was the highest priority market, followed by the rest of Asia (30.3%) and the ASEAN bloc (18.9%). By industry, exporters in almost every sector saw scaling up their activities on the Chinese Mainland as their priority.”Beyond the headline findings of the survey, a more detailed analysis highlights good news for Hong Kong exporters in terms of both individual market prospects and the likely future success of most of the city’s key industry sectors.Positive sentiments for major markets and key industry sectorsIn specific terms, turning to the Market Expectation Sub-Index, the Chinese Mainland (57.2) and the ASEAN bloc (57.0) are still considered to have significant growth potential. Predictably, this was less the case for the US (down 1.4 to 38.0), with the uncertainties in its trade environment continuing to unsettle Hong Kong exporters.Turning to individual industries, a number of sectors have expansionary expectations for the year ahead (i.e. had a relevant index reading of 50 or more). Topping the list is Jewellery (54.8), followed by Electronics (52.4), Timepieces (51.6) and Equipment/Materials (51.1).Despite such overall positive sentiments, the survey also points out the possibility that a number of challenges may lie ahead. Most notably, it cited rising labour and production costs (53.9%), growing logistics challenges (38.8%) and declining overseas orders on account of the general economic slowdown (38.2%) as potential future concerns.[1] On top of Trump 1.0 tariffs of ~20% on averageReferencesHong Kong 2026 Export Outlook: Sustained AI Product Demand Set to Drive 8-9% Growth Over Coming Year:https://research.hktdc.com/en/article/MjE4ODc2Mzk2NwHKTDC Export Confidence Index 4Q25: End-of-Year Figures Indicate Positive Expansion Prospects:https://research.hktdc.com/en/article/MjE4ODYyNTQwNwHKTDC Research website: https://research.hktdc.com/en/ Photo download: https://bit.ly/4oJPrPRHKTDC Director of Research Irina Fan (right) and HKTDC Section Head, Special Project & Business Advisory, Kenneth Lee (left) announced the HKTDC Export Confidence Index for 2025’s fourth quarter at a press conference todayHKTDC Director of Research Irina FanHKTDC Section Head, Special Project & Business Advisory Kenneth LeeMedia enquiriesPlease contact the HKTDC’s Communication and Public Affairs Department:Navin LawTel: (852) 2584 4525Email: navin.cm.law@hktdc.orgAgnes WatTel: (852) 2584 4554Email: agnes.ky.wat@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
雲頂新耀與海森生物簽署商業化服務協議及授權許可協議 推動商業化協同與多領域佈局 ACN Newswire

雲頂新耀與海森生物簽署商業化服務協議及授權許可協議 推動商業化協同與多領域佈局

香港, 2025年12月12日 - (亞太商訊 via SeaPRwire.com) - 雲頂新耀(Everest Medicines,HKEX 1952.HK)于2025年12月11日,宣佈其全資附屬公司雲頂新耀醫藥科技有限公司(以下簡稱:「雲頂新耀醫藥科技」)已與海森生物醫藥有限公司(以下簡稱:「海森生物」)簽署兩項戰略合作協議,包括商業化服務協議以及授權許可協議。根據商業化服務協議,雲頂新耀醫藥科技將依托現有的銷售與市場體系,為海森生物旗下六款成熟產品提供商業化服務。根據授權許可協議,雲頂新耀醫藥科技獲得在大中華區開展萊達西貝普(Lerodalcibep)的後續臨床開發、注冊和商業化的獨家許可。兩項協議將在財務與戰略上形成顯著協同效應,提升現有商業化平台的運營效率,加快雲頂新耀產品全生命周期、全渠道覆蓋的商業化能力建設,同時為公司在心血管疾病領域打造具有吸引力的業務版圖。通過此次合作,雲頂新耀將鞏固在中國的商業化基礎,提升市場份額,為心血管業務的長期增長注入核心動力,據了解,萊達西貝普(Lerodalcibep)有望於2027年在大中華區獲批,成為推動業務增長的關鍵引擎。商業化服務協同 提升多產品組合競爭力根據商業化服務協議,雲新耀醫藥科技將按相關產品季度淨銷售總額的20%-55%收取服務費。截至2028年12月31日的三年內,海森生物擬支付的年度交易金額上限分別為:2026年人民幣5.6億元、2027年人民幣6.16億元、2028年人民幣6.77億元。商業化服務協議涉及急重症、心血管和代謝三大領域,覆蓋六款成熟產品組合,包括急重症領域的羅氏芬(R)、思他寧(R)、亞寧定(R),心血管領域的易達比(R)、必洛斯(R)、以及代謝領域的倍欣(R),能夠充分發揮雲頂新耀現有商業化平台的優勢與佈局。其中,急重症領域的三款核心產品——羅氏芬(R)、思他寧(R)和亞寧定(R),憑借其在感染、消化系統急症及循環系統急症中的關鍵臨床地位,常被稱為「急重症三寶」。以羅氏芬(R)為例,作為廣譜第三代頭孢菌素,已覆蓋全國超過8,500家醫院,市場占有率超過80%,在複雜感染治療中保持長期、穩健的臨床需求。值得強調的是,在急重症領域,這三款藥物覆蓋的核心科室與公司精幹高效的依嘉(R)商業化團隊積累的核心醫院覆蓋和專業推廣能力高度重合,有望顯著提升產品市場滲透效率。隨著此次產品組合的加入,公司在急重症、心血管等重點治療領域的商業化佈局將得到進一步拓展,與現有商業化體系形成更強的協同效應,為商業化平台的規模化發展和收入提升提供更充足的支撐。引進Lerodalcibep 拓展心血管戰略佈局根據授權許可協議,雲頂新耀醫藥科技獲得在大中華區開展萊達西貝(Lerodalcibep)的後續臨床開發、注冊和商業化的獨家許可,並可在大中華區以免特許使用權費方式使用海森生物相關商標。雲頂新耀醫藥科技將支付2900萬美元(相當於約人民幣2.05億元)的初始付款,及最高不超過3000萬美元(相當於約人民幣2.12億元)的潛在開發及監管里程碑款項與最高不超過2.8億美元(相當於約人民幣19.77億元)的潛在銷售里程碑款項;以及按淨銷售額的潛在特許使用權費。萊達西貝普(Lerodalcibep)由美國私人公司LIB Therapeutics研發,是一款新型小分子蛋白結合的第三代PCSK9抑制劑,用於降低成人高膽固醇血症(包括雜合子型家族性高膽固醇血症(HeFH))患者的低密度脂蛋白膽固醇(LDL-C)水平。萊達西貝普(Lerodalcibep)經開發為更貼近患者需求、更加便捷的每月一針、單次小體積皮下注射制劑,居家旅行皆可方便儲存或攜帶。以上特點使萊達西貝普(Lerodalcibep)成為已獲批的PCSK9抑制劑的獨特替代方案。總計超過2,500例患者的多項全球大型三期臨床試驗結果顯示,萊達西貝普(Lerodalcibep)可使心血管疾病(CVD)患者或極高/高風險族群的LDL-C持續降低>60%,並使LDL-C升幅更嚴重的雜合家族性高膽固醇血症(FH)患者降低>55%,此外,另一項頭對頭臨床試驗(萊達西貝普vs英克司蘭)LIBerate-VI研究已取得優效結果(P=0.0319)。未來該產品的上市有望為全球億萬CVD患者(包括約3千萬FH患者)提供新的治療選擇。最新中國三期臨床試驗進一步證實,該療法可在已確診或處於極高心血管風險(包括家族性高膽固醇血症)的患者中顯著降低LDL-C水平。目前中國已有多款PCSK9抑制劑獲批上市,2024年總市場規模約人民幣30億元,同比增長95%。根據弗若斯特沙利文(Frost & Sullivan)報告,預計該市場將於2030年進一步擴大至約人民幣100億元。盡管中國血脂異常人群規模約4億,接受降脂治療的比例僅約14%,反映出滲透率偏低及顯著的未滿足醫療需求。萊達西貝普(Lerodalcibep)在中國的專利獨占期至2039年。雲頂新耀將萊達西貝普定位為「推動業務增長的關鍵引擎」,視其為公司在創新藥佈局中的「關鍵砝碼」。此舉被視為精准踐行了公司聚焦高潛力「藍海」領域、通過BD合作快速構建高價值產品組合的戰略,顯著充實了後期管線。市場觀點普遍認為,此次雙項協議實現了「短期收益可期、中長期成長清晰」的平衡。雲頂新耀可借助其已建立的醫學、准入、市場與銷售一體化協同體系,實現商業能力的高效輸出,提升資源利用效率,更向市場驗證了其商業化平台的可擴展性與運營韌性,展現出高效率、可持續的增長潛力。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
Everest Medicines Announces Commercialization Service Agreement and License Agreement with Hasten ACN Newswire

Everest Medicines Announces Commercialization Service Agreement and License Agreement with Hasten

HONG KONG, December 12, 2025 - (ACN Newswire via SeaPRwire.com) – Everest Medicines announced on Dec. 11, 2025 that its wholly-owned subsidiary, Everest Medicines (China) Co., Ltd (“Everest Medicines China”), has entered into two strategic agreements with privately held Hasten Biopharmaceutical Co., Ltd. (“Hasten”). The first is a Commercialization Services Agreement leveraging Everest's existing sales and marketing organization to provide commercialization services for a portfolio of Hasten's mature assets.The second is a License Agreement granting Everest the exclusive license to develop, register and commercialize Lerodalcibep, a novel, small protein-binding, third-generation PCSK9 inhibitor, which is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH) in Greater China.The two agreements are expected to create significant financial and strategic synergies, enhancing the operational efficiency of Everest’s existing commercial platform and accelerating the build-out of life-cycle and multi-channel commercialization capabilities. At the same time, they establish an attractive strategic footprint for the Company in the cardiovascular disease area. Through this collaboration, Everest will further strengthen its commercial foundation in China, expand market share, and inject core momentum into the long-term growth of its cardiovascular business. The potential approval of Lerodalcibep in Greater China in 2027 is expected to contribute to future revenue growth within Everest's cardiovascular portfolio.Commercialization Synergies to Strengthen Competitiveness Across a Multi-Product PortfolioEverest Medicines China will receive service fees from Hasten calculated by multiplying the net sales of each product for the applicable quarter by the applicable rate, which ranges from 20% to 55%. The proposed maximum annual caps for the transactions contemplated to be paid by Hasten for the three years ending December 31, 2028 are set at RMB 560 million in 2026, RMB 616 million in 2027, and RMB 677 million in 2028.The Commercialization Service Agreement covers six mature, commercially available products across three major therapeutic areas—critical care, cardiovascular disease, and metabolic disorders—including Rocephin(R), Stilamin(R), and Ebrantil(R) in critical care; Edarbi(R) and Blopress(R) in cardiovascular disease; and Basen(R) in metabolic disease. The portfolio is highly synergistic with Everest’s existing commercial infrastructure and strategic focus. Among them, the three core critical care products—Rocephin(R), Stilamin(R), and Ebrantil(R)—play an essential clinical role in the treatment of infectious, gastrointestinal emergency, and cardiovascular emergency conditions. Rocephin(R), for example, is a broad-spectrum, third-generation cephalosporin that has achieved coverage in more than 8,500 hospitals nationwide and holds over 80% market share, maintaining strong and sustained clinical demand in the treatment of complex infections. Notably, these transactions are expected to generate significant synergies for Everest by aligning XERAVA(R) with Hasten’s critical care portfolio — including Rocephin(R) and Stilamin(R) — across complementary geographic footprints, channel access and hospital coverage, while further strengthening the Company’s commercialization capabilities and life-cycle management of innovative medicines.With the addition of this product portfolio, the Company’s commercial presence in key therapeutic areas such as critical care and cardiovascular diseases will be further expanded, creating stronger synergies with its existing commercialization organization and providing more robust support for the scaled development and revenue growth of its commercial platform.Introduction of Lerodalcibep to Expand Strategic Footprint in Cardiovascular DiseasesThe agreement grants Everest the exclusive license to develop, register and commercialize Lerodalcibep in Greater China, together with a royalty-free, exclusive license to use Hasten's trademarks for the product in the territory. Pursuant to the license agreement, Everest Medicines China will make an initial payment of US$29 million (approximately RMB 205 million), and may pay up to US$30 million (RMB 212 million) in potential development and regulatory milestone payments and up to US$280 million (RMB1977 million) in potential sales milestones, in addition to royalties based on the total, aggregate annual net sales.Lerodalcibep, developed by privately-held and U.S.-based company LIB Therapeutics, is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). Lerodalcibep is a novel, small protein-binding, third-generation PCSK9 inhibitor, and has been developed as a more patient friendly and convenient, once-monthly, single small-volume, subcutaneous injection that will not require refrigeration at home or in travel. These features make Lerodalcibep a unique alternative to approved PCSK9 inhibitors. In large, global phase 3 clinical trials in over 2,500 patients, Lerodalcibep has demonstrated sustained LDL-C reductions of >60% in patients with, or at very-high or high risk of, cardiovascular disease (CVD) and >55% in those with heterozygous familial hypercholesterolemia (FH) who have more severe LDL-C elevations. In addition, the head-to-head LIBerate-VI study, comparing Lerodalcibep with Inclisiran, demonstrated the superiority of Lerodalcibep (p=0.0319). Lerodalcibep is expected to expand treatment options for the millions of patients around the world with CVD, including the 30 million individuals with FH. These LDL-C reductions have been confirmed in a recent phase 3 clinical trial in a Chinese population with, or at very high risk of, CVD including FH.Multiple PCSK9 inhibitors are currently approved and marketed in China, with a combined market size of approximately RMB 3 billion and year-over-year revenue growth of 95% in 2024. The market is expected to further increase to approximately RMB10 billion in 2030, according to a Frost & Sullivan report. Despite an estimated 400 million individuals in China with dyslipidemia, only ~14% receive lipid-lowering treatment, reflecting low penetration and significant unmet medical need. Lerodalcibep has patent exclusivity in China through 2039.Lerodalcibep is currently under regulatory review by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). In Greater China, Biologics License Application (BLA) submission is expected in 1H 2026, with the potential for approval in 2027.Everest considers Lerodalcibep an important future growth driver and a key addition to its innovative medicines portfolio. The transaction is viewed as aligned with the Company’s strategy to focus on high-potential therapeutic areas and to expand its late-stage pipeline through business development collaborations, thereby strengthening its overall portfolio.Market commentators note that the two agreements provide both near-term revenue contribution and clear longer-term growth opportunities. By leveraging its established medical, market access, marketing and sales capabilities, Everest is expected to improve the efficiency of its commercial operations and resource utilization, while further demonstrating the scalability and resilience of its commercial platform. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
國泰海通成功發行非銀金融機構首單上海自貿離岸債 ACN Newswire

國泰海通成功發行非銀金融機構首單上海自貿離岸債

香港, 2025年12月12日 - (亞太商訊 via SeaPRwire.com) - 12月11日,國泰海通集團下屬公司國泰君安國際控股有限公司(「國泰君安國際」或「公司」,股份代號:1788.HK)擔任配售代理牽頭行,協助國泰海通金融控股有限公司(以下簡稱「國泰海通金控」)成功發行非銀金融機構首單上海自貿離岸債,發行規模為5億元離岸人民幣,期限為364天,票面利率為1.8%,由上海清算所登記託管。本次發行是首單以中資券商為信用主體發行的上海自貿離岸債,同時為上海自貿離岸債發行以來單筆最大規模的發行之一。該筆發行遵循發行端、投資端「兩頭在外」原則,吸引諸多境外投資者在上海清算所開戶並踴躍認購,助力上海自貿離岸債投資者體系擴容,推動構建與上海國際金融中心相匹配的離岸金融體系。本次上海自貿離岸債為國泰海通金控更名後首次在國際資本市場亮相,國泰海通金控今年8月獲標普授予BBB+長期信用評級(展望「穩定」)後,年內陸續完成可交換債券和上海自貿離岸債的發行,進一步豐富其境外融資工具儲備、夯實了獨立境外融資能力。本次債券發行亦充分發揮了國泰海通集團內部的協同效應,國泰海通金控與集團總部統籌協調,由國泰君安國際、海通國際、海通銀行等聯合擔任配售代理機構,有力保障債券成功發行。關于國泰君安國際國泰海通集團下屬公司國泰君安國際(股票代號:1788.HK),是中國證券公司國際化的先行者和引領者,公司是首家通過IPO于香港聯合交易所主板上市的中資證券公司。國泰君安國際以香港爲業務基地,幷在新加坡、越南和澳門設立子公司,業務覆蓋全球主要市場,爲客戶境外資産配置提供高品質、多元化的綜合性金融服務,核心業務包括財富管理、機構投資者服務、企業融資服務、投資管理等。目前,國泰君安國際已分別獲得穆迪和標準普爾授予「Baa2」及「BBB+」長期發行人評級,MSCI ESG「A」評級, Wind ESG「A」評級及商道融綠ESG「A」評級,同時其標普全球ESG評分領先全球84%同業。公司控股股東國泰海通證券(股票代號:601211.SH/2611.HK)爲中國資本市場長期、持續、全面領先的綜合金融服務商。更多關于國泰君安國際的資訊請見:https://www.gtjai.com Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
紮根西藏 本土化團隊協同鑄就「礦業堡壘」!智匯礦業IPO背後的本土化競爭力 ACN Newswire

紮根西藏 本土化團隊協同鑄就「礦業堡壘」!智匯礦業IPO背後的本土化競爭力

香港, 2025年12月12日 - (亞太商訊 via SeaPRwire.com) - 今年以來,港股市場新股活躍度明顯回暖,不少具有成長屬性與獨特賽道優勢的企業受到市場關注。從資源、科技到新能源賽道,具備稀缺性、週期穿越能力與強現金流特徵的企業,更成為資金追逐的焦點。12月11日,西藏智匯礦業股份有限公司(「智匯礦業」)啟動港股招股,憑藉得天獨厚資源稟賦與穩健盈利屬性,引發市場廣泛關注。本次IPO,智匯礦業擬全球發售121,952,000股,招股價介乎4.10-4.51港元之間,預計於12月19日登陸聯交所。與依賴單一資源優勢的發展模式的礦業企業不同,智匯礦業已在高原深耕多年,通過本土化運營積澱、專業化團隊協同以及與當地生態的深度融合,構築起堅不可摧的 「礦業堡壘」。高原門檻成天然壁壘 本土化能力塑造獨特競爭力西藏高原因獨特的地理環境、氣候條件與文化背景,為礦業開發及運營設置了天然門檻,智匯礦業通過長期投入,構建其自身核心競爭力。自成立以來,公司始終堅持因地制宜的運營策略,將本土化貫穿于業務全流程,成功破解了高原礦業開發中的多重難題。其中,本地化的技術與管理團隊是智匯礦業穩定運營的前提。從地質勘探到采選排產,公司形成了對高原地質結構的精准理解,並建立起一支長期駐紮的專業團隊,使得生產組織能夠有效匹配高原環境的特性。在生產運營層面,公司建立了一套成熟的高原採礦適配體系。通過優化採礦流程、升級設備、建立彈性生產調度機制,使其在有限施工窗口中保持較高效率。生態治理和社區協同則構成其另一重軟實力。智匯礦業深度理解西藏地區礦業監管政策與生態保護要求,構建了完善的合規管理體系,制定了詳細的土地複墾計劃與環境修復方案,其蒙亞啊礦場成功入選自然資源部《綠色礦山名錄》,成為西藏礦業綠色發展的標杆企業。同時,智匯礦業積極融入西藏本地社區,通過在就業、民生、供應鏈協同方面積極作為,構建起穩定、可持續的本地合作生態,為業務穩定運營提供了堅實保障。優質礦山提供發展底盤 經營能力讓資源變為價值智匯礦業的核心資產蒙亞啊礦場,地處西藏岡底斯成礦帶這一國內重要多金屬成礦帶,本身就具備亮眼的資源稟賦。截至2025年7月31日,露天礦場的總礦石儲量為1,438.0千噸,平均品位分別為4.90%鋅、0.69%鉛、0.10%銅及10.09克╱噸銀;地下礦場儲量10,623千噸,平均品位分別為4.14%鋅、2.99%鉛、0.21%銅及35.00克╱噸銀,整體礦石品位處於較高水平。按合併基準,公司礦場服務年限約31年,為長期經營提供了充足資源底座。此外,公司還持有58.5平方公里的探礦權,增儲潛力充足,為未來產能擴張預留了空間。疊加政策支持下綠色礦山資質帶來的資源稅減免、所得稅優惠等政策紅利,資源端的優勢已十分突出。但相比資源本身,更值得關注的是,智匯礦業正在把複雜的高原礦山,轉化為「可預期的經營資產」。2024 年以來,隨著生產線升級完成以及地下礦場2025 年第二季度投產,產能迅速恢復,截至 7 月 31 日,公司實現營業收入 2.57 億元,同比增加253.39%,淨利潤 0.52 億元。公司短期内迅速调整生产模式实现营收充分證明公司管理體系的成熟度。在資源類企業中,「穩」往往比「多」更重要 —— 穩定的產能、穩定的回收率、穩定的成本控制,才能將靜態的資源儲量轉化為動態的持續利潤。智匯礦業既擁有優質資源稟賦,又具備將資源高效變現的運營能力,兩者兼具的特質讓其在行業中具備獨特競爭力。礦業高景氣持續,稀缺標的價值凸顯行業方面,中國鋅鉛精礦市場長期呈現結構性供應短缺,環保政策收緊與行業整合加速,讓具備綠色礦山資質、合規運營記錄良好的企業獲得更多資源傾斜;同時,西藏地區礦產資源開發門檻極高,自然環境、政策體系、社區協同等多重因素構成了強大的行業進入壁壘,新玩家難以短期突破,智匯礦業在本地深耕近20年,本身就是高原礦業極高壁壘的受益者。與此同時,精礦生產的下游需求的持續增長進一步放大其投資價值。鋅精礦在基建、光伏、風電等領域的需求穩步提升,鉛精礦作為鉛酸蓄電池的核心原材料,銅精礦作爲電力傳輸、電動汽車及可再生能源系統的「不可替代的戰略性金屬」,受益於新能源產業爆發式增長,几大核心產品的市場需求將長期保持景氣。智匯礦業憑藉穩定的供應能力、優質的產品品質,將持續受益行業需求增長紅利。總體而言,智匯礦業近二十年沉澱的本土化優勢,讓靜態的資源儲量轉化為動態的持續盈利,構築起堅固的「礦業堡壘」。未來,隨著地下礦場產能充分釋放與探礦權增儲潛力兌現,公司有望進一步鞏固區域龍頭地位,在行業新周期中迎來更大的價值兌現空間。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More

萬億工業賽道迎來「智慧樞紐」:解碼京東工業的價值邏輯

香港, 2025年12月11日 - (亞太商訊 via SeaPRwire.com) - 京東工業(07618.HK)正式登陸港交所,為京東生態資本市場佈局再添重要一子。面對一個規模超過11萬億人民幣、但數字化滲透率僅個位數的廣闊藍海,京東工業的上市,本質上是將其多年沉澱的工業專業知識、獨特商業模式與扎實財務表現,置於資本市場的放大鏡下,接受長期價值的審視與定價。公開資料顯示,京東工業通過「太璞」這一「數」「實」結合的全鏈路數智化工業供應鏈解決方案,提供廣泛的工業品供應和數智化供應鏈服務,以滿足客戶的多樣化需求。根據灼識諮詢的資料顯示,按2024年交易額計,京東工業為中國MRO採購服務市場的最大參與者,同時也是中國工業供應鏈技術與服務市場最大的服務提供商。專業深耕破痛點 行業 Know-How 築護城河京東工業的價值基底,建立在深厚的工業供應鏈專業知識之上。這絕非簡單的商品線上化,而是對工業品參數標準化、採購流程數字化、履約體系智能化的深刻理解與系統重構。受益於京東集團二十餘年管理複雜全鏈路供應鏈的深厚積澱,以及自身在工業領域的持續深耕與突破,京東工業積累涉足廣泛品類的深厚的產品領域知識,並將其系統化融入「太璞」解決方案之中。據了解,「太璞」已覆蓋從商品數智化、採購管理、智慧履約到運營服務的全鏈條,能夠為製造業、能源、交通等複雜行業的重點企業客戶,提供深度定制化的供應鏈優化方案。這種基於行業Know-how構建的專業壁壘,是競爭對手難以在短期內模仿和超越的,構成了公司長期價值的堅實內核。灼識諮詢資料顯示,2024年,公司在中國的工業供應鏈技術與服務市場擁有最廣泛的客戶覆蓋。2025年6月30日前的12個月內,京東工業服務著約1.1萬家重點企業客戶。2025年上半年,公司重點企業客戶包括約60%的中國《財富》 500強企業及逾40%的在華全球《財富》500強企業。這些對供應鏈穩定性、合規性有極高要求的巨頭選擇京東工業,本身就是對其專業服務能力最權威的背書。輕資產平臺撬動重工業生態 盈利路徑清晰在商業模式上,京東工業創新性地採用輕資產模式,徹底擺脫傳統貿易商「規模越大、管理越重」的增長瓶頸。公司通過其技術平台,智慧聚合客戶需求,並與上游十餘萬家製造商、分銷商和代理商的產能和庫存進行數字化連結與精准匹配,打造了行業領先的存貨周轉效率與管理能力。同時,其智慧履約系統整合了廣泛的第三方物流服務商,構建了一張彈性、高效的協同網絡。這種模式使得公司在業務規模快速擴張的同時,保持了優異的運營效率和健康的現金流。它本質上是用技術和數據驅動整個工業供應鏈的「存量資源」更高效地運轉,從而創造出巨大的增量價值。基於輕資產運營模式,京東工業打造了一個可擴展的商業模式,從而在工業供應鏈技術與服務市場建立了領先地位,並成功將業務版圖從通用MRO產品(廣泛運用於各行業應用場景下而設計及製造的非生產性物料,如工具、安防用品等)擴展到專業MRO產品(針對專業應用場景或需專業知識的產品,如化學品、儀器儀表、機器設備等),並正在向BOM產品(直接用於終端產品的生產物料,如電子元器件、緊固密封件)市場進一步滲透。數據顯示,2024 年中國 MRO 採購服務市場規模為人民幣 3.7 萬億元,而整個中國工業供應鏈市場規模則達到人民幣 11.4 萬億元,龐大的市場基盤為業務延伸提供了充足空間。與此同時,公司還將業務從國內擴展到特定海外市場,包括東南亞及若干其他有前景的地區,以支持重點企業客戶的海外擴張。財務數據是檢驗商業模式成功與否的最終尺規。2022年至2024年,公司營收從 141億元增長至204億元,複合年增長率達到20.1% ,2025 年上半年營收進一步增至 103 億元,擴張成果顯著;盈利水平亦同步提升,經調整淨利潤從2022年的7.1億元攀升至2024年的9.1億元,2025年上半年,公司經調整淨利潤達5.0億元,同比增長34.1%。隨著規模效應進一步釋放和海外業務的拓展提速,其盈利增長的能見度和確定性有望不斷增強。綜上所述,京東工業以專業深耕破局行業痛點,用模式創新打開價值空間,財務穩健增長,共同構成其長期投資價值的堅實支撐。此外,作為京東集團在產業端的重要佈局,京東工業共用「京東」的品牌信譽,能夠快速建立客戶信任;同时,京东工业可以高效利用集團在物流基礎設施、支付體系及底層技術方面的資源,強化服務保障。隨著上市後資本實力的增強與業務的持續擴張,公司在工業供應鏈數字化賽道的領先優勢將進一步擴大。對於著眼長期、聚焦價值的投資者而言,當前正是佈局這一工業供應鏈數智化龍頭的優質時機。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
國泰君安國際榮登《商業週刊》彭博綠金2026值得關注榜 – 綠色金融機構榜單 ACN Newswire

國泰君安國際榮登《商業週刊》彭博綠金2026值得關注榜 – 綠色金融機構榜單

香港, 2025年12月11日 - (亞太商訊 via SeaPRwire.com) - 近日,《商業週刊》彭博綠金2026值得關注榜單在上海正式發佈。國泰海通集團下屬公司國泰君安國際控股有限公司(「國泰君安國際」或「公司」,股份代號:1788.HK)憑藉在綠色金融領域的卓越表現與創新實踐,成功入選「綠色金融機構榜單」。國泰君安國際始終將綠色金融作為戰略發展的核心驅動力,系統構建了具有行業引領性的可持續發展金融體系。公司不僅將綠色理念全面融入投融資決策與業務運營,更通過創新產品與服務,積極推動低碳經濟轉型與長期價值共創。憑藉在綠色債券、碳資產管理和可持續投資等關鍵領域的深入實踐與突出成效,公司已贏得市場與監管機構的高度認可與持續信任。面向未來,國泰君安國際將進一步發揮專業優勢,持續拓展綠色金融產品矩陣,深化綠色金融工具創新與應用,不斷延伸綠色金融生態的廣度與深度,為經濟社會高品質發展注入持久綠色動能。彭博綠金隸屬於國際領先的媒體集團Bloomberg彭博,是全球及中國首個全面聚焦綠色經濟的媒體平台。近年來,彭博綠金推出多個具有行業影響力的權威榜單,積極引領並推動企業在可持續發展領域的卓越實踐。「綠色金融榜單」是彭博綠金首次推出的全新榜單,旨在響應國家綠色金融政策號召,推動金融機構與企業綠色轉型,助力實現「雙碳」目標。關于國泰君安國際國泰海通集團下屬公司國泰君安國際(股票代號:1788.HK),是中國證券公司國際化的先行者和引領者,公司是首家通過IPO于香港聯合交易所主板上市的中資證券公司。國泰君安國際以香港爲業務基地,幷在新加坡、越南和澳門設立子公司,業務覆蓋全球主要市場,爲客戶境外資産配置提供高品質、多元化的綜合性金融服務,核心業務包括財富管理、機構投資者服務、企業融資服務、投資管理等。目前,國泰君安國際已分別獲得穆迪和標準普爾授予「Baa2」及「BBB+」長期發行人評級,MSCI ESG「A」評級, Wind ESG「A」評級及商道融綠ESG「A」評級,同時其標普全球ESG評分領先全球84%同業。公司控股股東國泰海通證券(股票代號:601211.SH/2611.HK)爲中國資本市場長期、持續、全面領先的綜合金融服務商。更多關于國泰君安國際的資訊請見:https://www.gtjai.com Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
國泰君安國際蟬聯《信報財經新聞》上市公司卓越大獎 ACN Newswire

國泰君安國際蟬聯《信報財經新聞》上市公司卓越大獎

香港, 2025年12月11日 - (亞太商訊 via SeaPRwire.com) - 由香港專業財經媒體《信報財經新聞》主辦的「上市公司卓越大獎2025」頒獎典禮在香港成功舉辦。國泰海通集團下屬公司國泰君安國際控股有限公司(「國泰君安國際」或「公司」,股份代號:1788.HK)憑藉卓越表現,再度榮獲「主板」類別大獎,蟬聯此項殊榮。近年來,國泰君安國際持續推動多元化發展戰略,堅持穩健經營與風險管控並重,不斷深化業務佈局、推動創新轉型,實現財富管理、企業融資、投資管理等核心業務協同並進,整體經營質效顯著提升。展望未來,公司將繼續秉持「穩中求進」的發展基調,致力於構建覆蓋多元客戶群體的全週期綜合金融服務平台,推動可持續的高品質增長,為股東創造長期回報。《信報財經新聞》創刊於1973年,是香港首份以財經新聞為主的中文報紙,在業界享有廣泛影響力與權威性。「上市公司卓越大獎」評選已連續舉辦十屆,依託《信報》獨家研發的EJFQ「信號」系統,依據皮爾托斯基分數、專業分析師推薦頻次、股價表現及財務指標四大核心準則篩選入圍企業,並由行業領袖、商會代表、專業顧問及評審委員會共同審核,評選出表現卓越的上市公司。該獎項以其公正、專業的評選機制,在資本市場獲得高度認可。關于國泰君安國際國泰海通集團下屬公司國泰君安國際(股票代號:1788.HK),是中國證券公司國際化的先行者和引領者,公司是首家通過IPO于香港聯合交易所主板上市的中資證券公司。國泰君安國際以香港爲業務基地,幷在新加坡、越南和澳門設立子公司,業務覆蓋全球主要市場,爲客戶境外資産配置提供高品質、多元化的綜合性金融服務,核心業務包括財富管理、機構投資者服務、企業融資服務、投資管理等。目前,國泰君安國際已分別獲得穆迪和標準普爾授予「Baa2」及「BBB+」長期發行人評級,MSCI ESG「A」評級, Wind ESG「A」評級及商道融綠ESG「A」評級,同時其標普全球ESG評分領先全球84%同業。公司控股股東國泰海通證券(股票代號:601211.SH/2611.HK)爲中國資本市場長期、持續、全面領先的綜合金融服務商。更多關于國泰君安國際的資訊請見:https://www.gtjai.com Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
康哲藥業(0867)抗急性缺血性卒中創新藥注射用Y-3中國NDA獲受理 ACN Newswire

康哲藥業(0867)抗急性缺血性卒中創新藥注射用Y-3中國NDA獲受理

深圳, 2025年12月11日 - (亞太商訊 via SeaPRwire.com) - 康哲藥業控股有限公司("康哲藥業")欣然宣佈,1類新藥注射用Y-3(擬定中文通用名:注射用洛貝米柳)("注射用Y-3"或"產品")新藥上市許可申請(NDA)已於2025年12月11日獲得中國國家藥品監督管理局(NMPA)受理。產品為一種擬用於急性缺血性卒中的腦細胞保護劑。注射用Y-3靶點明確,作用機制清晰,可發揮多重療效。注射用Y-3作為全球首個基於腦卒中病理過程重要靶點PSD95-nNOS和MPO開發的腦細胞保護劑,作用於缺血性腦卒中缺血級聯反應多個關鍵病理過程,通過多靶點高選擇性協同,更有利於發揮腦細胞保護作用。產品具有優異的治療缺血性腦卒中和潛在的預防卒中後抑鬱焦慮症狀的作用。注射用Y-3臨床數據優異,療效優異,安全性佳。產品中國II期臨床試驗研究結果表明,在發病48小時內的缺血性腦卒中患者中,使用Y-3 40mg 每日一次治療後,達到90天優良功能結局(mRS評分0~1分)的患者比例較安慰劑組顯著提高,率差達到16%。產品中國Ⅲ期臨床研究由首都醫科大學附屬北京天壇醫院任組長單位,于全國近40家研究中心納入發病時間≤48小時的急性缺血性腦卒中患者近1,000例,旨在評價注射用Y-3治療發病在48小時以內的急性缺血性腦卒中患者的有效性和安全性。Ⅲ期臨床研究達到主要療效終點,患者臨床獲益明顯,整體安全性良好。主要研究結果未來計劃在國際學術會議上公佈,整體研究將在國際學術期刊上發表。中樞神經系統(CNS)是康哲藥業的核心優勢領域之一,已逐步形成深度佈局。產品組合包括在售創新藥維圖可(地西泮鼻噴霧劑)、原研品牌藥黛力新(氟哌噻噸美利曲辛片)以及處於NDA審評中的改良型新藥ZUNVEYL(葡萄糖酸苯加蘭他敏腸溶片),已夯實市場基礎。注射用Y-3的加入,將進一步強化產品矩陣,在專家網絡與市場資源上產生高效協同。期待注射用Y-3早日上市,為中國缺血性腦卒中患者帶來療效優異、作用更全面的新一代腦細胞保護劑,並憑藉集團卓越的商業化經驗與合規高效的運營體系,加速推動創新療法惠及更多患者。關於注射用Y-3的更多信息急性缺血性腦卒中的病理過程高度複雜且相互關聯,臨床亟需多靶點多機制協同干預,以實現對複雜的缺血級聯反應的更有效調控,從而提高治療效果和患者生活質量。注射用Y-3可解離PSD95-nNOS耦聯,抑制MPO活性,還可增強α2-GABAA受體(一種具有抗抑鬱、抗焦慮功能的GABAA受體亞型)活性,通过這種多靶點高選擇性協同機制,有望實現"卒中治療與卒中後抑鬱焦慮預防"同步干預的技術突破,使注射用Y-3有望成為一種療效優異,作用更全面的新型腦細胞保護劑。於2024年第十屆歐洲卒中組織會議(ESOC 2024)上以口頭壁報形式發表的注射用Y-3治療急性缺血性卒中的II期臨床試驗研究結果表明,在發病48小時內的缺血性腦卒中患者中,使用Y-3(20mg、40mg、60mg,每日一次)治療後達到90天優良功能結局(mRS評分0~1分)的患者比例顯著高於安慰劑組(20mg: 67.8% vs 60.7%、40mg: 76.7% vs 60.7%、60mg: 70.0% vs 60.7%)。且產品在急性缺血性腦卒中人群的安全性與安慰劑相當,表現出良好的耐受性。於2023年8月24日,康哲藥業通過其全資附屬公司與一家以臨床需求為導向、創新與研發驅動的新藥企業南京寧丹新藥技術股份有限公司就產品簽署合作協議("協議")。根據協議,康哲藥業獲得產品在中國大陸、香港特別行政區、澳門特別行政區的獨家推廣權。協議期限為永久。關於腦卒中根據國家衛健委發布的《腦血管病防治指南(2024年版)》,我國每年新發卒中約394萬例,占全球新發病例三分之一,其中缺血性卒中占比約72%,年新發病例超280萬;現患病的卒中患者已超2,800萬人[1]。2021年中國死因監測數據顯示,卒中死亡占全國總死亡人數的23%[1]。過去三十年,我國卒中相關殘疾的疾病負擔持續加重,疊加人口老齡化加快等因素,未來卒中防控壓力將進一步增大,給患者家庭和社會帶來巨大挑戰[1]。此外,卒中後抑鬱和焦慮是卒中常見並發症,發病率分別達到約30%和25%[2],會影響患者神經功能恢複,甚至增加死亡風險,嚴重影響患者預後。注射用Y-3對廣大卒中患者長期神經功能改善和總體預後具有重大潛在價值,市場前景廣闊。關於康哲藥業康哲藥業是一家鏈接醫藥創新與商業化,把控產品全生命週期管理的開放式平台型企業,致力於提供有競爭力的產品和服務,滿足尚未滿足的醫療需求。康哲藥業專注於全球首創(FIC)及同類最優(BIC)的創新產品,並高效推進創新產品臨床研究開發和商業化進程,賦能科研成果向診療實踐的持續轉化,造福患者。康哲藥業聚焦專科領域,擁有被驗證的商業化能力,廣泛的渠道覆蓋和多疾病領域專家資源,核心在售產品已獲領先的學術與市場地位。康哲藥業圍繞優勢專科領域不斷縱深發展,以鞏固心腦血管/消化/眼科/皮膚健康業務競爭力,帶來專科規模效率,其中皮膚健康業務(德鎂醫藥)已成為其細分領域的龍頭企業,並擬於聯交所獨立上市。同時,康哲藥業持續推動研產銷全產業鏈在東南亞及中東區域運營發展,以獲取新興市場的增量,助力集團實現高質量可持續發展。參考文獻/資料1.中華人民共和國國家衛生健康委員會. 腦血管病防治指南(2024年版)[J]. 磁共振成像, 2025, 16(1): 1-8. DOI: 10.12015/issn.1674-8034.2025.01.001.2.陳杏雨, 呂小涵, 李瑞娜, 等. 卒中後焦慮[J]. 國際腦血管病雜誌, 2022, 30(2) : 129-133. DOI: 10.3760/cma.j.issn.1673-4165.2022.02.010.康哲藥業免責與前瞻性聲明本新聞無意向您做任何產品的推廣,非廣告用途。本新聞不對任何藥品和醫療器械和/或適應症作推薦。若您想瞭解具體疾病診療信息,請遵從醫生或其他醫療衛生專業人士的意見或指導。醫療衛生專業人士作出的任何與治療有關的決定應根據患者的具體情況並遵照藥品說明書。由康哲藥業編制的此新聞不構成購買或認購任何證券的任何要約或邀請,不形成任何合約或任何其他約束性承諾的依據或加以依賴。本新聞由康哲藥業根據其認為可靠之資料及數據編制,但康哲藥業並無進行任何說明或保證、明述或暗示,或其他表述,對本新聞內容的真實性、準確性、完整性、公平性及合理性不應加以依賴。本新聞中討論的若干事宜可能包含涉及康哲藥業的市場機會及業務前景的陳述,該等陳述分別或統稱為前瞻性聲明。該等前瞻性聲明並非對未來表現的保證,存在已知及未知的風險、不明朗性及難以預知的假設。康哲藥業並不採納本新聞包含的第三方所做的任何前瞻性聲明及預測,康哲藥業對該等第三方聲明及預測不承擔責任。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
CMS (867/8A8): NDA of Innovative Drug Y-3 for Injection for Acute Ischemic Stroke Accepted in China ACN Newswire

CMS (867/8A8): NDA of Innovative Drug Y-3 for Injection for Acute Ischemic Stroke Accepted in China

SHENZHEN, Dec 11, 2025 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that on 11 December 2025, the New Drug Application (NDA) of Class 1 Innovative Drug Y-3 for Injection (proposed English generic name: Loberamisal for Injection) (“Y-3 for Injection” or the “Product”) has been accepted by National Medical Products Administration of the People’s Republic of China (NMPA). The Product is a brain cytoprotectant indicated for the treatment of acute ischemic stroke.With well-defined targets and clear mechanism of action, Y-3 for Injection is able to exert multiple therapeutic effects. As the world’s first brain cytoprotectant developed based on the important targets PSD95-nNOS and MPO, in the pathological processes of stroke, Y-3 for Injection acts on multiple key pathological processes of the ischemic cascade in ischemic stroke. Through multi-target, highly selective synergy, it is more conducive to exerting brain cytoprotective effects. The Product has an excellent therapeutic effect on ischemic stroke and the potential to prevent post-stroke depression and anxiety symptoms.Y-3 for Injection demonstrates excellent clinical data with excellent efficacy and a favorable safety profile. The results of Phase II clinical trial of the Product in China indicated that among patients with ischemic stroke within 48 hours of onset, patients in the Y-3 group (40mg, qd) demonstrated a significantly higher proportion of patients achieving an excellent functional outcome (mRS of 0-1) at 90 days than those in the placebo group, with a rate difference of 16%. The Phase III clinical trial of the Product in China was conducted by Beijing Tiantan Hospital, Capital Medical University as the leading site. It has enrolled nearly 1,000 patients with acute ischemic stroke within 48 hours of onset across approximately 40 research centers nationwide, aiming to evaluate the efficacy and safety of Y-3 for Injection in treating patients with acute ischemic stroke within 48 hours of onset. The Phase III clinical study met the primary efficacy endpoint, with patients achieving significant clinical benefits and an overall favorable safety profile. The key study results are planned to be presented at international academic conferences, and the full study will be published in international academic journals.The Central Nervous System (CNS) is one of the core advantageous fields of CMS, where a deeply integrated layout has been progressively established. The product portfolio has solidified the market foundation, including the marketed innovative drug VALTOCO (Diazepam Nasal Spray), the original brand drug Deanxit (Flupentixol and Melitracen Tablets), and the improved new drug ZUNVEYL (Benzgalantamine Gluconate Enteric-coated Tablets), which is currently under NDA review. The addition of Y-3 for Injection will further strengthen the product portfolio, generating highly efficient synergies in terms of expert networks and market resources. It is expected that if approved for marketing, Y-3 for Injection will bring a new generation of brain cytoprotectant with excellent efficacy and more comprehensive therapeutic effects to Chinese patients with ischemic stroke. Leveraging the successful commercialization experience and compliant and efficient operation system, the Group will accelerate the accessibility of innovative therapies to benefit more patients.More Information about Y-3 for InjectionThe pathological processes of acute ischemic stroke are highly complex and interconnected. There is an urgent clinical need for multi-target, multi-mechanism coordinated interventions to achieve more effective regulation of the complex ischemic cascade, thereby improving treatment outcomes and enhancing patients’ quality of life. Y-3 for Injection is able to uncouple PSD95-nNOS, inhibit MPO activity, and enhance the activity of α2-GABAA receptor (a subtype of GABAA receptor with antidepressant and anxiolytic effects). With this multi-target, highly selective synergistic mechanism, it is expected to achieve a technological breakthrough in the simultaneous intervention of “stroke treatment and prevention of post-stroke depression and anxiety”, making Y-3 for Injection a promising novel brain cytoprotectant with excellent efficacy and more comprehensive therapeutic effects.The results of Phase II clinical trial of Y-3 for Injection for the treatment of acute ischemic stroke were presented as an oral poster at the 10th European Stroke Organisation Conference in 2024 (ESOC 2024). It indicated that among patients with ischemic stroke within 48 hours of onset, patients in the Y-3 group (20mg, 40mg, 60mg, qd) demonstrated a significantly higher proportion of patients achieving an excellent functional outcome (mRS of 0-1) at 90 days than those in the placebo group (20mg: 67.8% vs 60.7%, 40mg: 76.7% vs 60.7%, 60mg: 70.0% vs 60.7%). Moreover, the Product showed comparable safety to placebo in acute ischemic stroke patients, exhibiting good tolerability.On 24 August 2023, the Group through its wholly-owned subsidiary entered into a Collaboration Agreement (the “Agreement”) with Neurodawn Pharmaceutical Co., Ltd. (“NeuroDawn”), a clinical needs-oriented pharmaceutical company driven by innovation and R&D. In accordance with the Agreement, the Group obtains an exclusive promotion right in mainland China, the Hong Kong Special Administrative Region, and the Macau Special Administrative Region. The term of the Agreement is permanent.About StrokeAccording to the Guideline for Prevention and Treatment of Cerebrovascular Disease (2024 Edition) issued by the National Health Commission, approximately 3.94 million new stroke cases occur in China each year, accounting for one-third of the global new cases[1]. Among these, ischemic stroke accounts for about 72%, with over 2.8 million new cases annually; the number of existing stroke patients in China has exceeded 28 million[1]. Data from China’s cause-of-death monitoring in 2021 shows that stroke-related deaths accounted for 23% of the national total deaths[1]. Over the past three decades, the disease burden of stroke-related disabilities in China has continued to increase[1]. Coupled with factors such as the accelerating aging of the population, the pressure of stroke prevention and control will further intensify in the future, posing enormous challenges to patients’ families and society[1]. In addition, post-stroke depression and anxiety are common complications of stroke, with incidence rates of approximately 30% and 25% respectively[2]. They can hinder the recovery of patients’ neurological functions, even increase the risk of death, and severely affect patients’ prognosis. Y-3 for Injection holds significant potential value for the long-term neurological function improvement and overall prognosis of a vast number of stroke patients, indicating broad market prospects.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.Reference1. National Health Commission of the People’s Republic of China. Guideline for Prevention and Treatment of Cerebrovascular Disease (2024 Edition) [J]. Chinese Journal of Magnetic Resonance Imaging, 2025, 16(1): 1-8. DOI: 10.12015/issn.1674-8034.2025.01.001.2. Chen Xinyu, Lyu Xiaohan, Li Ruina, et al. Post-Stroke Anxiety [J]. International Journal of Cerebrovascular Disease, 2022, 30(2): 129-133. DOI: 10.3760/cma.j.issn.1673-4165.2022.02.010.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More